3-aza-bicyclo[3.1.0]hexane derivative, preparation method therefor and use thereof
By developing 3-aza-bicyclic[3.1.0]hexane derivatives as SSTR4 receptor agonists, the problem of insufficient selectivity and stability of existing SSTR4 agonists is solved, and effective treatment of central nervous system diseases is achieved. and pain relief, with good oral efficacy and pharmacokinetic properties.
Patent Information
- Application Number
- PCT/CN2024/094789
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-29
- Filing Date
- 2024-05-22
- Publication Date
- 2024-12-05
AI Technical Summary
There are fewer receptor agonists for human somatostatin SSTR4, and natural SST has a wide range of effects, but is not selective and has a short half-life, making it difficult to be used for long-term chronic diseases, especially for poor oral efficacy.
Develop a 3-aza-bicyclic[3.1.0]hexane derivative as an agonist of SSTR4 receptors, which improves its agonism on SSTR4 receptors through specific compound structures and preparation methods, and can be used for the preparation of treatments. and drugs to prevent diseases related to the central nervous system.
This compound has a good agonistic effect on human somatostatin SSTR4 receptor and can be used to prepare drugs for the treatment and prevention of diseases related to the central nervous system, especially in pain and osteoarthritis, and has Good oral absorption characteristics and stability.
Smart Images

Figure CN2024094789_05122024_PF_FP_ABST
Abstract
Description
3-Aza-bicyclo[3.1.0]hexane derivatives, preparation methods and uses thereof Technical Field
[0001] The present invention relates to a 3-aza-bicyclo[3.1.0]hexane derivative, a preparation method and application thereof. Background Art
[0002] The somatostatin receptor family (SSTRs) is a family of G protein-coupled receptors that mediate the diverse biological effects of somatostatin and its analogs. Their physiological functions and mechanisms of action have long garnered significant attention. Studies have shown that these specific membrane receptors, including SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5, play important roles in regulating GH secretion, inducing apoptosis, inhibiting tumor cell proliferation, inhibiting insulin action, and inhibiting cell growth through cAMP, PTP, and MAPK signaling pathways. They also exhibit kinetic properties similar to those of other G protein-coupled receptors. Somatostatin (SST) is a cyclic polypeptide widely distributed in the central nervous system and peripheral tissues. It is a growth hormone-inhibiting releasing hormone (GH-releasing hormone) isolated and purified from the ovine hypothalamus by Brazeau et al. in 1973. It exists in vivo as a 14-peptide (SST-14) and a 28-peptide (SST-28). Research results indicate that SST, as a signaling molecule, is mediated by a family of somatostatin receptors (SSTRs) on the cell membrane. SST has only two forms, and the complexity of SST's physiological functions is reflected in the complexity of its receptors. Therefore, the biological significance of SSTRs is, to some extent, even more important than that of SST.
[0003] The amino acid sequences of human somatostatin receptor (hSSTR) subtypes share 40% to 60% homology. Taylor et al. confirmed that SSTR2 has two variants, SSTR2A and SSTR2B. Of the five subtypes, except for SSTR5, which binds to SST28 10-30 times more strongly than SST14, all subtypes have high affinity for SST14 and SST28. Somatostatin is involved in regulating processes such as cell proliferation, glucose homeostasis, inflammation, and pain. In this regard, somatostatin or other members of the somatostatin peptide family are believed to inhibit pain and inflammatory processes via the SSTR4 pathway. The selective SSTR4 agonist J-2156 has been disclosed, for example, in Biomedicine & Pharmacotherapy, 117 (2019), 109056, and has been reported to have analgesic effects in animals. Other patents WO2016075239, WO2016075240, and WO2014184275 report the application of SSTR4 agonists in the field of analgesia.
[0004] Natural SSTs have a broad range of effects, limited selectivity, and a short half-life (approximately 1 minute). Consequently, a variety of somatostatin analogs (SSTAs) have been synthesized to enhance their effects and prolong their half-life. Synthetic SSTAs include the octapeptide analogs octreotide (SMS201995), lanreotide (BIM2304), and vapreotide (RC-160); the heptapeptide analog TT-232; and the hexapeptide analog seglitide (MK-678). These octapeptide analogs have plasma half-lives >90 minutes and high receptor affinity, but are poorly absorbed orally, making them unsuitable for long-term chronic conditions such as pain. Therefore, there is an urgent need to develop stable, highly selective, and orally effective non-peptide SSTR4 agonists to meet clinical needs.
[0005] Summary of the Invention
[0006] The present invention aims to solve the technical problem that there are few agonists for the human somatostatin SSTR4 receptor. The present invention provides a 3-aza-bicyclo[3.1.0]hexane derivative, a preparation method and use thereof. The compound has a good agonistic effect on the human somatostatin SSTR4 receptor and can be used to prepare a drug for treating and / or preventing diseases related to the central nervous system.
[0007] The present invention provides a compound as shown in Formula I or a pharmaceutically acceptable salt thereof,
[0008] in,
[0009] R1 H or C 1-6 alkyl;
[0010] R 2 H or C 1-6 alkyl;
[0011] R 3 and R 4 Independently H, C 1-6 Alkyl or C 3-6 Cycloalkyl;
[0012] Or, R 3 、R 4 Together with the carbon atoms it is connected to, it forms C 3-6 Cycloalkyl;
[0013] L is a bond, -CH2-, -CH2-CH2- or -CH2-O-;
[0014] X 1 CR X1 or N;
[0015] X 2 CR X2 or N;
[0016] X 3 CR X3 or N;
[0017] X 4 CR X4 or N;
[0018] R X1 、R X2 、R X3 、R X4 and R 5 are independently H, halogen, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkynyl, 1, 2 or 3 R a Substituted C 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)-C 1-4 Alkyl or "a 4-membered heterocycloalkyl group having one heteroatom selected from N, O and S";
[0019] R X1 、R X2 、R X3 、R X4 and R5 At least one of them is C 2-6 Alkynyl, 1, 2 or 3 R a Substituted C 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)-C 1-4 Alkyl or "a 4-membered heterocycloalkyl group wherein the heteroatom is selected from one of N, O and S, and the number of the heteroatom is one";
[0020] R a are independently hydroxy, halogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, "a 3- to 6-membered heterocycloalkyl group having one, two or three heteroatoms selected from N, O and S, and having one or two heteroatoms".
[0021] In a preferred embodiment, R X1 、R X2 、R X3 , and R X4 are independently H, halogen, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkynyl, 1, 2 or 3 R a Substituted C 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)-C 1-4 Alkyl or "a 4-membered heterocycloalkyl group having one heteroatom selected from N, O and S";
[0022] R 5 C 2-6 Alkynyl or 1, 2 or 3 R a Substituted C 2-6 Alkynyl; R 5 Preferably C 2-6 Alkynyl.
[0023] In a preferred embodiment, R X1 、R X2 、R X3 , and R X4 are independently H, halogen, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkynyl, 1, 2 or 3 R a Substituted C2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)-C 1-4 Alkyl or "a 4-membered heterocycloalkyl group having one heteroatom selected from N, O and S"; and R X1 、R X2 、R X3 , and R X4 At least one is not H; preferably R X3 Not for H;
[0024] R 5 C 2-6 Alkynyl or 1, 2 or 3 R a Substituted C 2-6 Alkynyl; R 5 Preferably C 2-6 Alkynyl.
[0025] In a preferred embodiment, certain groups in the compound of formula I are defined as follows (unmentioned groups are the same as those described in any embodiment of the present application, hereinafter referred to as "in a preferred embodiment"):
[0026] R 1 、R 2 、R X1 、R X2 、R X3 、R X4 and R 5 In the C 1-6 Alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
[0027] In a preferred embodiment, R 3 、R 4 , and R a In the C 1-6 Alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl; for example, methyl.
[0028] In a preferred embodiment, R 1 、R 2 、R 3 、R 4 、R X1 、R X2 、R X3 、R X4 、R 5 and R a In the C 3-6 Cycloalkyl is independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0029] In a preferred embodiment, R3 、R 4 Together with the carbon atoms it is connected to, it forms C 3-6 In the cycloalkyl group, the C 3-6 Cycloalkyl is independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0030] In a preferred embodiment, R a In the C 3-6 Cycloalkyl is independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; for example, cyclopropyl.
[0031] In a preferred embodiment, R X1 、R X2 、R X3 、R X4 and R 5 In the C 1-6 The haloalkyl groups are independently C 1-4 Halogenated alkyl.
[0032] In a preferred embodiment, R X1 、R X2 、R X3 、R X4 and R 5 In the C 1-6 Alkoxy is independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.
[0033] In a preferred embodiment, R X1 、R X2 、R X3 、R X4 and R 5 In the C 1-6 The haloalkoxy groups are independently C 1-4 Halogenated alkoxy.
[0034] In a preferred embodiment, R 5 In the C 2-6 Alkynyl and the substituted C 2-6 C in the alkynyl group 2-6 Alkynyl groups are independently
[0035] In a preferred embodiment, R X1 、R X2 、R X3 and R X4 In, the -OC 3-6 Cycloalkyl is
[0036] In a preferred embodiment, R 5In, the -OC 3-6 Cycloalkyl is For example
[0037] In a preferred embodiment, R X1 、R X2 、R X3 , and R X4 In the above, the “4-membered heterocycloalkyl group having one heteroatom selected from the group consisting of N, O and S” is an oxetanyl group.
[0038] In a preferred embodiment, R 5 In the embodiment, the “4-membered heterocycloalkyl group having one heteroatom selected from N, O and S” is an oxetane group (e.g. ).
[0039] In a preferred embodiment, R a In the above, the “heteroatoms selected from 1, 2 or 3 of N, O and S, and the number of heteroatoms is 1, 2 or 3 3-membered heterocycloalkyl” means “heteroatoms selected from O, and the number of heteroatoms is 1 3-6 membered heterocycloalkyl”; for example, oxetane (e.g. ).
[0040] In a preferred embodiment, R X1 、R X2 、R X3 , and R X4 In the -C(=O)-C 1-4 The alkyl groups are independently
[0041] In a preferred embodiment, R 5 In the -C(=O)-C 1-4 The alkyl groups are independently For example
[0042] In a preferred embodiment, R X1 、R X2 、R X4 and R 5 wherein the halogen is F, Cl, Br or I.
[0043] In a preferred embodiment, R X3 wherein the halogen is F, Cl, Br or I; for example, F or Cl.
[0044] In a preferred embodiment, R awherein the halogen is F, Cl, Br or I; for example, F.
[0045] In a preferred embodiment, R 1 For H.
[0046] In a preferred embodiment, R 2 For H.
[0047] In a preferred embodiment, R 3 and R 4 Independently C 1-6 alkyl.
[0048] In a preferred embodiment, L is -CH2-O-.
[0049] In a preferred embodiment, X 1 CR X1 or N; X 2 CR X2 ;X 3 CR X3 ;X 4 CR X4 .
[0050] In a preferred embodiment, R X1 、R X2 、R X3 and R X4 are independently H, halogen or -CN;
[0051] Preferably, R X1 、R X2 and R X4 are independently H; R X3 is H, halogen or -CN;
[0052] More preferably, R X1 、R X2 and R X4 are independently H; R X3 is halogen or -CN.
[0053] In a preferred embodiment, R 5 C 2-6 Alkynyl, 1, 2 or 3 R a Substituted C 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)-C 1-4 Alkyl or "a 4-membered heterocycloalkyl group having one heteroatom selected from N, O and S";
[0054] Preferably C 2-6 Alkynyl, 1, 2 or 3 R a Substituted C2-6 Alkynyl.
[0055] In a preferred embodiment, R a are independently hydroxy, halogen, C 1-6 Alkyl, C 3-6 Cycloalkyl or "a 3- to 6-membered heterocycloalkyl group having one, two or three heteroatoms selected from N, O and S, with one or two heteroatoms".
[0056] In a preferred embodiment, R 1 is H;
[0057] R 2 is H;
[0058] R 3 and R 4 Independently C 1-6 alkyl;
[0059] L is -CH2-O-;
[0060] X 1 CR X1 or N; X 2 CR X2 ;X 3 CR X3 ;X 4 CR X4 ;
[0061] R X1 、R X2 、R X3 and R X4 are independently H, halogen or -CN;
[0062] R 5 C 2-6 Alkynyl, 1, 2 or 3 R a Substituted C 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)-C 1-4 Alkyl or "a 4-membered heterocycloalkyl group having one heteroatom selected from N, O and S";
[0063] R a are independently hydroxy, halogen, C 1-6 Alkyl, C 3-6 Cycloalkyl or "a 3- to 6-membered heterocycloalkyl group having one, two or three heteroatoms selected from N, O and S, with one or two heteroatoms".
[0064] In a preferred embodiment, R 3 and R 4 is independently -CH3.
[0065] In a preferred embodiment, R 5 for
[0066] In a preferred embodiment, R X1 、R X2 、R X3 , and R X4 are independently H, halogen, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkynyl, 1, 2 or 3 R a Substituted C 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)-C 1-4 Alkyl or "a 4-membered heterocycloalkyl group having one heteroatom selected from N, O and S"; and R X1 、R X2 、R X3 , and R X4 Among them, at least one is not H;
[0067] R 5 for
[0068] In a preferred embodiment, R X1 、R X2 、R X3 , and R X4 are independently H, halogen, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkynyl, 1, 2 or 3 R a Substituted C 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)-C 1-4 Alkyl or "a 4-membered heterocycloalkyl group having one heteroatom selected from N, O and S"; and R X3 Not for H;
[0069] R 5 for
[0070] In a preferred embodiment, R X1 、R X2, and R X3 are independently H, halogen or -CN; R X4 is halogen or -CN;
[0071] R 5 for
[0072] In a preferred embodiment, for For example
[0073] In a preferred embodiment, the compound represented by formula I is a compound represented by formula IA:
[0074] Among them, X 1 、R X3 and R 5 The definition of is as described in any one of the present invention.
[0075] In a preferred embodiment, in Formula IA, R 5 C 2-6 Alkynyl or -C(=O)-C 1-4 Alkyl; R X3 is halogen or -CN.
[0076] The compound shown in formula I is selected from any one of the following compounds:
[0077] The present invention also provides a method for preparing the compound of formula I, comprising the following steps: mixing the compound of formula II with an acid in a solvent to obtain the compound of formula I;
[0078] R 1 is H; PG is an amino protecting group (such as a Boc group);
[0079] R 2 ,R 3 ,R 4 ,R 5 ,X 1 ,X 2 ,X 3 ,X 4 The definitions of and L are as described in any one of the present invention.
[0080] The present invention also provides a compound as shown in Formula II or a pharmaceutically acceptable salt thereof,
[0081] R 2 ,R3 ,R 4 ,R 5 ,X 1 ,X 2 ,X 3 ,X 4 and L are defined as above;
[0082] PG is an amino protecting group (eg, a Boc group).
[0083] The compound represented by formula II is selected from any one of the following compounds:
[0084] The present invention also provides a pharmaceutical composition comprising (a therapeutically effective amount of) the compound represented by Formula I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical excipient.
[0085] The selection of the pharmaceutical excipients varies depending on the route of administration and the characteristics of the action, and can generally be fillers, diluents, binders, wetting agents, disintegrants, lubricants, emulsifiers, suspending agents, etc. conventional in the art.
[0086] The present invention also provides a use of the compound represented by formula I, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition in the preparation of an SSTR4 receptor agonist.
[0087] The SSTR4 receptor agonist can be used to prepare medicines for treating and / or preventing diseases related to the central nervous system.
[0088] The SSTR4 receptor agonist can be used to prepare a drug for treating and / or preventing pain or osteoarthritis. The pain can be acute pain, neuropathic peripheral pain or chronic pain.
[0089] The disease related to the central nervous system may be Alzheimer's disease, epilepsy or depression.
[0090] In the aforementioned applications, the SSTR4 receptor agonist can be used in mammals in vivo; it can also be used in vitro, primarily for experimental purposes, for example, as a standard or control sample for comparison, or prepared into a kit according to conventional methods in the art to provide rapid detection of the effects of the SSTR4 receptor agonist.
[0091] The present invention also provides a use of the compound as shown in Formula I, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition for preparing a drug for treating and / or preventing diseases related to the central nervous system.
[0092] The diseases related to the central nervous system are mediated through the SSTR4 pathway.
[0093] The disease may be Alzheimer's disease, epilepsy or depression.
[0094] The disease may be pain or osteoarthritis. The pain may be acute pain, neuropathic peripheral pain or chronic pain.
[0095] the term
[0096] Unless otherwise specified, the following terms appearing in the present specification and claims have the following meanings:
[0097] The term "pharmaceutically acceptable salt" refers to a salt obtained by reacting a compound with a pharmaceutically acceptable acid or base. When the compound contains a relatively acidic functional group, a base addition salt can be obtained by contacting the compound with a sufficient amount of a pharmaceutically acceptable base in a suitable inert solvent. When the compound contains a relatively basic functional group, an acid addition salt can be obtained by contacting the compound with a sufficient amount of a pharmaceutically acceptable acid in a suitable inert solvent. For details, see Handbook of Pharmaceutical Salts: Properties, Selection, and Use (P. Heinrich Stahl, Camille G. Wermuth, 2011, 2nd Revised Edition).
[0098] At the end of the structural fragment It means that the structural fragment is connected to the rest of the molecule through this site. For example, It refers to an oxetane group.
[0099] A "-" at the end of a group indicates that the group is attached to the rest of the molecule through that site. For example, -CN refers to a cyano group.
[0100] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0101] The term "alkyl" refers to a group having the specified number of carbon atoms (e.g., C 1-6 Alkyl refers to a linear or branched, saturated, monovalent hydrocarbon group. Alkyl includes, but is not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, etc.
[0102] The term "alkoxy" refers to the group RO-, where R is defined as the same as the term "alkyl." Alkoxy includes, but is not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and the like.
[0103] The term "alkynyl" refers to a group having the specified number of carbon atoms (e.g., C 2-6 Alkynyl, C 2-4Alkynyl), a linear or branched, unsaturated, monovalent hydrocarbon group having one or more (e.g., 1, 2, or 3) carbon-carbon sp 3 Triple bond. Alkynyl includes but is not limited to: ethynyl, wait.
[0104] The term "cycloalkyl" refers to a cycloalkyl group having the specified number of carbon atoms (e.g., C 3-6 Cyclic, saturated, monovalent hydrocarbon group, which is a monocyclic ring. Cyclic alkyl groups include but are not limited to: wait.
[0105] The term "heterocycloalkyl" refers to a cyclic, saturated, monovalent group having a specified number of ring atoms (e.g., 3-6 membered heterocycloalkyl), a specified number of heteroatoms (e.g., 1, 2, or 3), and a specified type of heteroatom (one, two, or three of N, O, and S), which is a single ring. The heterocycloalkyl group is attached to the rest of the molecule through a carbon atom or a heteroatom. Heterocycloalkyl groups include, but are not limited to: wait.
[0106] The term "haloalkyl" is an "alkyl" substituted with one or more (eg, 1, 2 or 3) halogens; the "alkyl" is defined as the term "alkyl"; the "halogen" is defined as the term "halogen".
[0107] The term "haloalkoxy" refers to an "alkoxy" substituted with one or more (eg, 1, 2 or 3) halogens; the "alkoxy" is defined as the term "alkoxy"; and the "halogen" is defined as the term "halogen".
[0108] The term "therapeutically effective amount" refers to an amount administered to a patient that is sufficient to effectively treat a disease. The therapeutically effective amount will vary depending on the type of compound, the type of disease, the severity of the disease, the age of the patient, etc., but can be adjusted by those skilled in the art as appropriate.
[0109] The term "pharmaceutical excipients" refers to all substances contained in pharmaceutical preparations other than the active pharmaceutical ingredient (API). These substances are generally classified into two categories: excipients and additives. For details, see the Pharmacopoeia of the People's Republic of China (2020 Edition) and the Handbook of Pharmaceutical Excipients (Paul J Sheskey, Bruno C Hancock, Gary P Moss, David J Goldfarb, 2020, 9th Edition).
[0110] The term "treat" refers to eliminating the cause or alleviating the symptoms of a disease.
[0111] The term "prevent" refers to reducing the risk of developing a disease.
[0112] The term "patient" refers to any animal, typically a mammal, such as a human, that needs to be treated or prevented. Mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, and the like.
[0113] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain preferred embodiments of the present invention.
[0114] The reagents and raw materials used in the present invention are commercially available.
[0115] The positive progress of the present invention is that the compounds of the present application have a good agonist effect on the human somatostatin SSTR4 receptor and can be used to prepare drugs for treating and / or preventing diseases related to the central nervous system. BRIEF DESCRIPTION OF THE DRAWINGS
[0116] FIG1 is a graph showing the efficacy of the rat CFA model in Test Example 3, wherein two-way ANOVA with Dunnett's multiple comparison test was used, with *p<0.05, **p<0.01, ***p<0.001 compared with the Vehicle (solvent control group).
[0117] FIG2 is a graph showing the mechanical allodynia test of rats in Test Example 4. DETAILED DESCRIPTION
[0118] The present invention is further illustrated by way of examples below, but the present invention is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.
[0119] 1,4-dioxane is 1,4-dioxane, i.e.
[0120] Example 1
[0121] Synthesis of BX20-7-007
[0122] Step 1: Synthesis of intermediate S2
[0123] The synthetic route is shown below:
[0124] Methods: Compound S1 (1.00 g, 4.48 mmol), Et3N (1.36 g, 13.4 mmol), and CuI (86 mg, 0.45 mmol) were added sequentially to DMF (10.0 mL). After nitrogen displacement, a 1 M solution of propyne in DMF (5.37 mL, 5.37 mmol) was added. The reaction mixture was allowed to react in a sealed tube at room temperature for 12 h. After completion of the reaction, water (60 mL) was added and the mixture was extracted with ethyl acetate (25 mL x 3). The organic phase was dried and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE / EA = 10 / 1, V / V) to afford compound S2 as a yellow solid (420 mg, 69.4% yield). MS (ESI, m / z) 136.2 [M+H] + .
[0125] Step 2: Synthesis of intermediate S3
[0126] Method: Compound Int S1 (780 mg, 8.76 mmol) was dissolved in 1,4-dioxane (10 mL). NaH (60%, 372 mg, 9.3 mmol) was added and stirred at room temperature for 10 minutes. S2 (420 mg, 3.11 mmol) was then added and stirred at 100°C for 1 hour. After completion of the reaction, the mixture was quenched with water and extracted with DCM (25 mL x 3). The mixture was washed with brine, and the organic phase was dried and concentrated under reduced pressure at 40°C to afford S3 (600 mg, crude) as a yellow oil. MS (ESI, m / z) 205.2 [M+H] + .
[0127] Step 3: Synthesis of intermediate S4
[0128] Method: Int 1 (280 mg, 1.23 mmol) was dissolved in anhydrous DMF (5 mL), and HATU (703 mg, 1.85 mmol) and TEA (372 mg, 3.69 mmol) were added. After stirring the reaction mixture at room temperature for half an hour, S3 (410 mg, crude product) was added and the reaction was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was extracted with ethyl acetate, washed with brine, and dried over anhydrous sodium sulfate. The residue was concentrated and purified by column chromatography (PE:EA = 2:1, V / V) to obtain S4 (300 mg, 59.1% yield) as a light yellow solid. MS (ESI, m / z) 414.2 [M+H] + .
[0129] Step 4: Synthesis of intermediate BX20-7-007
[0130] Methods: S4 (300 mg, 0.72 mmol) was dissolved in DCM (10 mL) and TFA (1 mL) was added dropwise. The reaction was stirred at room temperature for 3 hours. After completion, the reaction solution was concentrated and MeOH (10 mL) was added to adjust the pH to 9-10. The product was purified by preparative chromatography (formic acid system, column: Phenomenex luna C18 150×25 mm 10 μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (0.225% FA), B: acetonitrile; elution gradient: phase B from 1% to 25% over 15 min). After lyophilization, the product BX20-7-007 (160 mg, yield: 70.4%) was obtained as an off-white powder. MS (ESI, m / z) 314.3 [M+H] + .
[0131] 1 H NMR (400MHz, DMSO-d6) δ=8.29-8.25(m,1H),8.07(dd,J=5.2Hz,J=2.0Hz,1H),7.78(brs,1H),7.72(dd,J=7.6Hz,J=2.0Hz,1 H),6.94(dd,J=7.6Hz,J=5.2Hz,1H),4.35(s,2H),3.10-3.01(m,4H),2.07(s,3H),1.80(s,2H),1.65(brs,1H),1.33(s,6H).
[0132] Example 2
[0133] Synthesis of BX20-7-Q01
[0134] Step 1: Synthesis of intermediate S2
[0135] The synthetic route is shown below:
[0136] Method: Compound S1 (5.0 g, 22.5 mmol), PdCl2(PPh3)2 (1.26 g, 1.8 mmol), CuI (0.68 g, 3.6 mmol), Et3N (3.54 g, 35 mmol), and DMF (80 mL) were added sequentially. The N2 atmosphere was replaced, and SO (3.29 g, 33.6 mmol) was added. The reaction mixture was stirred at 20°C for 12 h. After completion of the reaction, the mixture was filtered through Celite, extracted with EA, and washed with saturated brine. The organic phase was dried, concentrated under reduced pressure, and purified by column chromatography (PE / EA = 100:1 to 50:1, V / V) to obtain compound S2 (3.2 g, 74.1%) as a brown oil. MS (ESI, m / z) 193 [M+H] + .
[0137] Step 2: Synthesis of intermediate S3
[0138] The synthetic route is shown below:
[0139] Method: Compound S2 (3.2 g, 16.6 mmol) was dissolved in THF (10 mL) under ice-cooling. Water (1 mL) was added, and TBAF (1 M in THF, 17 mL) was added dropwise. The reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, the mixture was extracted with EA, washed with saturated brine, and the organic phase was dried, concentrated under reduced pressure, and purified by column chromatography (PE:EA = 20:1, V / V) to afford S3 (900 mg, 44.5%) as a light yellow solid. MS (ESI, m / z) 122 [M+H] + .
[0140] Step 3: Synthesis of intermediate S4
[0141] The synthetic route is shown below:
[0142] Method: Compound Int S1 (1.6 g, 18.5 mmol) was dissolved in 1,4-dioxane (40 mL) at room temperature. NaH (760 mg, 19 mmol) was added portionwise. After stirring for 30 min, S3 (900 mg, 7.4 mmol) was added. After addition, the reaction mixture was heated to 100°C and stirred for 1 h. After completion of the reaction, the reaction mixture was poured into saturated ammonium chloride solution to quench the reaction. The mixture was extracted with DCM, and the organic phase was dried and concentrated under reduced pressure to obtain compound S4 (1.4 g, crude) as a brown oil. MS (ESI, m / z) 191 [M+H] + .
[0143] Step 4: Synthesis of intermediate S5
[0144] The synthetic route is shown below:
[0145] Methods: Compound Int S2 (250 mg, 1.1 mmol) was dissolved in DMF (10 mL). HATU (950 mg, 2.5 mmol) and TEA (263 mg, 2.6 mmol) were added sequentially. After stirring for 10 min, S4 (247 mg, crude product, approximately 1.2 mmol) was added. The reaction mixture was stirred at 25°C for 1 h. After completion of the reaction, the reaction mixture was quenched by adding water, extracted with EA, washed with brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (PE:EA = 1:1, V / V) to afford compound S5 (310 mg, 70.0%) as a colorless oil. MS (ESI, m / z) 400 [M+H] + .
[0146] Step 5: Synthesis of BX20-7-Q01
[0147] The synthetic route is shown below:
[0148] Methods: Compound S5 (310 mg, 0.7 mmol) was dissolved in DCM (20 mL), and TFA (4.5 mL) was added. The reaction mixture was stirred at 25°C for 3 h. After completion of the reaction, the reaction mixture was concentrated and dissolved in methanol (10 mL). The pH was adjusted to 10 with NaOH solution (1 N). The product was purified by preparative chromatography (formic acid system, column: Phenomenex luna C18 150×25mm 10μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (0.225% FA), B: acetonitrile; elution gradient: phase B from 1% to 25% over 15 min) to obtain compound BX20-7-Q01 (140 mg, 66.8%) as a yellow-brown solid. MS (ESI, m / z) 300 [M+H] + .
[0149] 1 H NMR (400MHz, DMSO-d6) δ = 8.23 (s, 1H), 8.13 (dd, J = 4.8, 1.6 Hz, 1H), 7.84-7.80 (m, 2H), 6.97 (dd, J =7.2,4.8Hz,1H),4.38(s,1H),4.35(s,2H),3.15(s,4H),1.86(s,2H),1.61(s,1H),1.31(s,6H).
[0150] Example 3
[0151] Synthesis of BX20-7-Q13
[0152] Step 1: Synthesis of intermediate S2
[0153] The synthetic route is shown below:
[0154] Method: Compound S1 (5.0 g, 22.5 mmol), PdCl2(PPh3)2 (0.79 g, 1.13 mmol), CuI (0.43 g, 2.25 mmol), Et3N (6.82 g, 67.5 mmol), and DMF (20 mL) were added sequentially. The N2 atmosphere was replaced, and SO (27 mL, 1.0 M in DMF) was added. The reaction mixture was stirred at 20°C for 12 h. After completion of the reaction, the mixture was filtered through Celite and washed with EA. The filtrate was collected and extracted with saturated brine. The organic phase was dried. After concentration under reduced pressure, the mixture was purified by column chromatography (PE:EA = 20:1, V / V) to afford Compound S2 (2.6 g, 86.2%) as a pale yellow oil.
[0155] Step 2: Synthesis of intermediate S3
[0156] The synthetic route is shown below:
[0157] Method: Compound Int S1 (4.78 g, 53.7 mmol) was dissolved in 1,4-dioxane (70 mL) and DMF (14 mL). NaH (2.22 g, 55.5 mmol) was added portionwise. After stirring for 30 min, S2 (2.40 g, 17.9 mmol) was added. The reaction mixture was heated to 100°C and stirred for 6 h. After completion of the reaction, the reaction mixture was poured into saturated ammonium chloride solution for quenching, extracted with EA, and the organic phase was dried and concentrated under reduced pressure to obtain compound S3 (0.3 g, crude) as a brown oil. MS (ESI, m / z) 204 [M+H] + .
[0158] Step 3: Synthesis of intermediate S4
[0159] The synthetic route is shown below:
[0160] Method: Compound Int S2 (0.40 g, 1.8 mmol) was dissolved in DMF (10 mL) and stirred until clear. HATU (0.89 g, 2.3 mmol) and TEA (0.45 g, 4.5 mmol) were added sequentially and stirred for 10 min. S3 (0.6 g, 3.0 mmol) was then added and the reaction mixture was stirred at 25°C for 1 h. After completion of the reaction, the reaction mixture was quenched by adding ice water, extracted with EA, washed with brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (PE:EA = 1:1, V / V) to afford compound S4 (0.46 g, 61.1%) as a colorless oil. MS (ESI, m / z) 413 [M+H] + .
[0161] Step 4: Synthesis of BX20-7-Q13
[0162] The synthetic route is shown below:
[0163] Methods: Compound S4 (0.46 g, 1.1 mmol) was dissolved in DCM (15 mL) and stirred until clear. TFA (1.5 mL) was added, and the reaction mixture was stirred at 25°C for 12 h. After completion of the reaction, the reaction mixture was quenched by adding ice water, extracted with EA, washed with brine, dried over anhydrous sodium sulfate, concentrated, and purified by preparative chromatography (formic acid system, column: Phenomenex luna C18 150×25 mm 10 μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (0.225% FA), B: acetonitrile; elution gradient: phase B from 10% to 30% over 15 min) to afford compound BX20-7-Q13 (30 mg, 8.7%) as a yellow solid. MS (ESI, m / z) 313 [M+H] + .
[0164] 1 H NMR(400MHz, DMSO-d6)δ8.24(s,1H),7.70(s,1H),7.27(dd,J=7.5,1.7Hz,1H),7.25-7.20(m,1H),6.92(dd,J=8.3,1.0Hz,1H), 6.89-6.83(m,1H),4.06(s,2H),3.03(t,J=9.6Hz,4H),2.03(s,3H),1.77(d,J=2.3Hz,2H),1.60(t,J=3.2Hz,1H),1.33(s,6H).
[0165] Example 4
[0166] Synthesis of BX20-7-Q14
[0167] Step 1: Synthesis of intermediate S0
[0168] The synthetic route is shown below:
[0169] Method: Compound A1 (1.00 g, 11.2 mmol), Et3N (1.13 g, 11.2 mmol), and (Boc)2O (2.29 g, 10.5 mmol) were added sequentially to DCM (20.0 mL) and stirred at room temperature for 3 hours. After completion of the reaction, saturated ammonium chloride (30 mL) was added and extracted. The organic phase was dried and concentrated under reduced pressure at 40°C to afford compound S0 (2.1 g, crude) as a white solid. MS (ESI, m / z) 212.2 [M+Na] + .
[0170] Step 2: Synthesis of intermediate S1
[0171] Method: A solution of compound S0 (9.0 g, crude) in ACN (50 mL) was added dropwise to ACN (50 mL) containing SOCl2 (8.6 mL) at -40°C. After stirring for 5 minutes, pyridine (13.5 mL) was added and stirring continued for half an hour. The mixture was then heated to 0°C and stirred for another half an hour. After completion of the reaction, the mixture was quenched with dilute hydrochloric acid (1 M), extracted with EA, washed with NaHCO3 solution, and then washed with brine. The organic phase was dried and concentrated under reduced pressure at 40°C to afford S1 (8.5 g, crude) as a yellow oil. MS (ESI, m / z) 236 [M+H] + .
[0172] Step 3: Synthesis of intermediate S3
[0173] Method: S2 (8.5 g, crude) was dissolved in ACN (100 mL) and H2O (100 mL). NaIO4 (9.6 g, 44.9 mmol) and RuCl3·xH2O (55 mg, 0.25 mmol) were added. The reaction was stirred at 0°C for 30 minutes and then at room temperature for 30 minutes. After completion of the reaction, ether was added for extraction. The organic phase was washed with brine, dried over anhydrous sodium sulfate, and concentrated to yield S3 (8.6 g, crude) as a white solid. MS (ESI, m / z) 252 [M+H] + .
[0174] Step 4: Synthesis of intermediate S4
[0175] Method: Dissolve S3 (2.5 g, crude) in DMF (25 mL), add K2CO3 (4.1 g, 29.7 mmol) and A2 (2.1 g, 9 mmol), and stir at 80°C for 12 hours. After completion of the reaction, quench with water, extract with ethyl acetate, wash with brine, dry over anhydrous sodium sulfate, and concentrate to obtain a yellow solid S4 (4.0 g, crude). MS (ESI, m / z) 410 [M+H] + .
[0176] Step 5: Synthesis of intermediate S5
[0177] The synthetic route is shown below:
[0178] Methods: Compound S4 (1.9 g, 4.5 mmol), Pd(PPh3)2Cl2 (180 mg, 0.27 mmol), Et3N (1.45 g, 14.5 mmol), and CuI (108 mg, 0.54 mmol) were added sequentially to DMF (25 mL). After nitrogen displacement, a 1 M solution of propyne in DMF (7.2 mL, 7.2 mmol) was added. The reaction mixture was allowed to react at room temperature for 12 h. The reaction was quenched with water and extracted with ethyl acetate. The organic phase was dried and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE:EA = 3:1, V / V) to afford S5 (1.0 g, 68.8%) as a yellow solid. MS (ESI, m / z) 322 [M+H] + .
[0179] Step 6: Synthesis of intermediate S6
[0180] Method: Dissolve S5 (1.0 g, 0.23 mmol) in anhydrous DCM (15 mL) and add TFA (2.5 mL) dropwise. Stir the reaction at room temperature for 1 hour. After completion, the reaction solution is concentrated to obtain a brown oily liquid S6 (1.6 g, crude product). MS (ESI, m / z) 222 [M+H] + .
[0181] Step 7: Synthesis of intermediate S7
[0182] Method: Int 1 (300 mg, 1.32 mmol) was dissolved in DMF (10 mL). HATU (570 mg, 1.5 mmol) and TEA (600 mg, 6 mmol) were added sequentially. The mixture was stirred at room temperature for 10 minutes before S6 (500 mg, crude product, approximately 1.5 mmol) was added and stirred at room temperature for 1 hour. The reaction mixture was quenched by pouring into water, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (PE:EA = 2:1, V / V) afforded S7 (488 mg, 86.0% yield) as a yellow oil. MS (ESI, m / z) 431 [M+H] + .
[0183] Step 8: Synthesis of BX20-7-Q14
[0184] Method: S7 (488 mg, 1.1 mmol) was dissolved in DCM (10 mL) and TFA (2 mL) was added dropwise. The reaction was stirred at room temperature for 1 hour. After completion, the reaction solution was concentrated and water (20 mL) was added to adjust the pH to 9-10. The solution was extracted with DCM / MeOH, washed with brine, dried over anhydrous sodium sulfate, and purified by column chromatography (DCM:MeOH = 10:1, V / V). After concentration and lyophilization, BX20-7-Q14 (260 mg, 71.6%) was obtained as a light yellow solid. MS (ESI, m / z) 331 [M+H] + .
[0185] 1 H NMR (400MHz, DMSO-d6) δ = 7.55 (s, 1H), 7.13-7.04 (m, 2H), 6.94 (dd, J = 9.2Hz, 4.8Hz, 1H), 7.08 (dd, J = 7.6Hz, J = 4.8Hz, 1H), 4 .04(s,2H),2.86(d,J=10.8Hz,2H),2.74(d,J=10.8Hz,2H),2.04(s,3H),1.61(brs,2H),1.48(q,J=7.2Hz,1H),1.31(s,6H).
[0186] Example 5
[0187] Synthesis of BX20-7-Q15
[0188] Step 1: Synthesis of intermediate S2
[0189] The synthetic route is shown below:
[0190] Method: Compound S1 (2.0 g, 8.1 mmol), PdCl2(PPh3)2 (0.29 g, 0.41 mmol), CuI (0.16 g, 0.81 mmol), Et3N (2.45 g, 24.3 mmol), and DMF (10 mL) were added sequentially. The N2 atmosphere was replaced, and SO (9.7 mL, 1.0 M in DMF) was added. The reaction mixture was stirred at 20°C for 12 h. After completion, the reaction mixture was filtered through Celite and washed with EA. The filtrate was collected and extracted with saturated brine. The organic phase was dried. After concentration under reduced pressure, the product was purified by column chromatography (PE:EA = 10:1, V / V) to afford compound S2 (0.94 g, 72.8%) as a yellow solid.
[0191] Step 2: Synthesis of intermediate S3
[0192] The synthetic route is shown below:
[0193] Method: Compound Int S1 (1.58 g, 17.7 mmol) was dissolved in 1,4-dioxane (35 mL). NaH (0.73 g, 18.3 mmol) was added portionwise. After stirring for 30 min, S2 (0.94 g, 5.9 mmol) was added. The reaction mixture was heated to 100°C and stirred for 1 h. After completion of the reaction, the reaction mixture was poured into saturated ammonium chloride solution for quenching, extracted with DCM, and the organic phase was dried and concentrated under reduced pressure to obtain compound S3 (0.76 g, 55.9%) as a brown solid. MS (ESI, m / z) 229 [M+H] + .
[0194] Step 3: Synthesis of intermediate S4
[0195] The synthetic route is shown below:
[0196] Method: Compound Int S2 (0.20 g, 0.88 mmol) was dissolved in DMF (10 mL) and stirred until clear. HATU (0.44 g, 1.14 mmol) and TEA (0.22 g, 2.20 mmol) were added sequentially and stirred for 10 min. S3 (0.35 g, 1.53 mmol) was then added and the reaction mixture was stirred at 25°C for 1 h. After completion of the reaction, the reaction mixture was quenched by adding ice water, extracted with EA, washed with brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (PE:EA = 1:1, V / V) to afford compound S4 (0.36 g, 93.2%) as a white solid. MS (ESI, m / z) 438 [M+H] + .
[0197] Step 4: Synthesis of BX20-7-Q15
[0198] The synthetic route is shown below:
[0199] Methods: Compound S4 (0.36 g, 1.1 mmol) was dissolved in anhydrous DCM (10 mL) and stirred until clear. TFA (1 mL) was added, and the reaction mixture was stirred at 25°C for 3 h. After completion, the reaction mixture was quenched by adding ice water, extracted with EA, washed with brine, dried over anhydrous sodium sulfate, concentrated, and purified by preparative chromatography (formic acid system, column: Phenomenex luna C18 150×25mm 10μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (0.225% FA), B: acetonitrile; elution gradient: phase B from 5% to 25% over 15 min) to afford compound BX20-7-Q15 (190 mg, 50.9%) as a yellow solid. MS (ESI, m / z) 338 [M+H]+ .
[0200] 1 H NMR (400MHz, DMSO-d6) δ8.27(s,1H),7.80(s,1H),7.75(d,J=2.1Hz,1H),7.71(dd,J=8.6,2.2Hz,1H),7.12(d,J=8 .7Hz,1H),4.19(s,2H),3.03(d,J=3.3Hz,4H),2.07(s,3H),1.77(d,J=2.4Hz,2H),1.64-1.60(m,1H),1.33(s,6H).
[0201] Example 6
[0202] Synthesis of BX20-7-Q16
[0203] Step 1: Synthesis of intermediate S2
[0204] The synthetic route is shown below:
[0205] Methods: Compound S1 (5.0 g, 44.6 mmol) was dissolved in DMA (100 mL). CsCO (43.6 g, 133.8 mmol), KI (2.2 g, 13.4 mmol), and NaI (2.0 g, 13.4 mmol) were added sequentially. The N2 atmosphere was replaced, and Al (16.2 g, 133.8 mmol) was added. The reaction mixture was heated to 150°C in a sealed tube and stirred for 8 h. After completion of the reaction, the filtrate was filtered and collected. The product was concentrated under reduced pressure and purified by column chromatography (PE:EA = 10:1, V / V) to afford compound S2 (3.9 g, 57.6%) as a colorless oil.
[0206] Purification gave compound S2 (3.9 g, 57.6%) as a colorless oil.
[0207] Step 2: Synthesis of intermediate S3
[0208] The synthetic route is shown below:
[0209] Method: Compound A2 (4.4 g, 49.3 mmol) was dissolved in 1,4-dioxane (100 mL), and NaH (2.0 g, 50.8 mmol) was added. After stirring for 30 min, S2 (2.5 g, 16.4 mmol) was added. The reaction mixture was heated to 100°C and stirred for 2 h. After completion of the reaction, the reaction mixture was poured into saturated ammonium chloride solution for quenching, extracted with DCM, and the organic phase was dried and concentrated under reduced pressure to obtain compound S3 (0.15 g, 4.1%) as a brown oil. MS (ESI, m / z) 222 [M+H] + .
[0210] Step 3: Synthesis of intermediate S4
[0211] The synthetic route is shown below:
[0212] Method: Compound A3 (0.15 g, 0.68 mmol) was dissolved in DMF (10 mL) and stirred until clear. HATU (0.34 g, 0.88 mmol) and TEA (0.17 g, 1.70 mmol) were added sequentially and stirred for 10 min. S3 (0.15 g, 0.68 mmol) was then added and the reaction mixture was stirred at 25°C for 3 h. After completion of the reaction, the reaction mixture was quenched by adding ice water, extracted with EA, washed with brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (PE:EA = 1:1, V / V) to afford compound S4 (0.20 g, 69.1%) as a colorless oil. MS (ESI, m / z) 431 [M+H] + .
[0213] Step 4: Synthesis of BX20-7-Q16
[0214] The synthetic route is shown below:
[0215] Methods: Compound S4 (0.20 g, 0.47 mmol) was dissolved in DCM (5 mL) and stirred until clear. HCl / 1,4-dioxane (1.2 mL, 4.0 M in 1,4-dioxane) was added, and the reaction mixture was stirred at 25°C for 2 h. After completion of the reaction, the reaction mixture was quenched by adding ice water, extracted with EA, washed with brine, dried over anhydrous sodium sulfate, concentrated, and purified by preparative chromatography (HCl system, column: Phenomenex luna C18 150×25mm 10μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (0.05% HCl v / v), B: acetonitrile; elution gradient: phase B from 12% to 32% over 15 min) to afford compound BX20-7-Q16 (118 mg, 76.1%) as a yellow solid. MS (ESI, m / z) 331 [M+H] + .
[0216] 1 H NMR (400MHz, DMSO-d6) δ9.72(s,1H),9.32(s,1H),7.85(s,1H),7.18(dd,J=7.3,2.5Hz,1H),6.94-6.84(m,3H),3.97(s,2H),3.85(tt, J=6.1,3.0Hz,1H),3.35-3.19(m,4H),1.91(d,J=3.0Hz,2H),1.72(t,J=3.4Hz,1H),1.29(s,6H),0.76-0.69(m,2H),0.68-0.60(m,2H).
[0217] Example 7:
[0218] Synthesis of BX20-7-Q17
[0219] Step 1: Synthesis of intermediate A2
[0220] The synthetic route is shown below:
[0221] Methods: Compound A1 (20.0 g, 120.48 mmol) was dissolved in DMF (200 mL). K2CO3 (19.35 g, 140.22 mmol) was added. BnBr (24.0 g, 141.18 mmol) was dissolved in DMF (50 mL) and added dropwise to the A1 DMF solution. The mixture was stirred at room temperature for 18 h. After completion of the reaction, the reaction solution was added dropwise to H2O (500 mL) and extracted with ethyl acetate (400 mL x 2). The organic phase was washed with saturated NaCl solution, dried, and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE / EA = 2 / 1, V / V) to afford Compound A2 (28.6 g, 92.7% yield) as a white solid. MS (ESI, m / z) 257.1 [M+H] + .
[0222] Step 2: Synthesis of Intermediate A3
[0223] Methods: Compound A2 (28.6 g, 111.72 mmol) was dissolved in THF (150 mL). NaH (60%, 13.4 g, 335.0 mmol) was added at 0°C and stirred for 30 minutes. SM1 (50 mL) was then added and the reaction was stirred at 65°C for 3 hours. After completion of the reaction, the reaction solution was poured into saturated NH4Cl solution (200 mL) for quenching. The mixture was extracted with EA (200 mL × 3) and washed with saturated NaCl solution. The organic phase was dried and concentrated under reduced pressure at 40°C. Purification by column chromatography (PE / EA = 3 / 1, V / V) afforded Compound A3 (34.4 g, 98.1% yield) as a white solid. MS (ESI, m / z) 315.1 [M+H] + .
[0224] Step 3: Synthesis of Intermediate A4
[0225] Methods: LiAlH4 (10.35 g, 272.3 mmol) was dissolved in anhydrous THF (300 mL) at 0°C and stirred at 0°C. A3 (28.5 g, 90.76 mmol) was dissolved in THF (200 mL) and slowly added dropwise to the LiAlH4 THF solution. The reaction was stirred at room temperature for 3 hours. After completion of the reaction, the reaction solution was stirred at 0°C and quenched by the slow addition of H2O (10.35 mL), 15% NaOH solution (10.35 mL), and H2O (31.05 mL). The reaction solution was stirred for 15 minutes and filtered through ethyl acetate (200 mL). The reaction solution was washed with saturated NaCl solution, dried over anhydrous Na2SO4, and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE:EA = 0:1, V / V) to obtain A4 (11.4 g, 48.7% yield) as a white solid. MS (ESI, m / z) 259.1 [M+H] + .
[0226] Step 4: Synthesis of Intermediate A5
[0227] Methods: A4 (5.0 g, 19.38 mmol) was dissolved in THF (140 mL) and stirred at 0°C under N2 protection. The N2 was replaced three times. n-BuLi (8.1 mL) was added and stirred at 0°C for 0.5 h. TsCl (3.7 g, 19.38 mmol) was dissolved in THF (30 mL) and added. The mixture was stirred at 0°C for 1 h. n-BuLi (8.1 mL) was then added and stirred at 60°C for 4.5 h. After completion of the reaction, the reaction solution was quenched by dropwise addition of saturated NH4Cl solution (100 mL). The mixture was extracted with ethyl acetate (100 mL × 3). The organic phase was washed with saturated NaCl solution, dried over anhydrous Na2SO4, and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE:EA = 5:1, V / V) to afford the compound as a yellow oily liquid (3.3 g, 71.0% yield). MS (ESI, m / z) 241.1 [M+H] + .
[0228] Step 5: Synthesis of Intermediate A6
[0229] Method: Under a hydrogen atmosphere, A5 (3.3 g, 13.75 mmol) was dissolved in MeOH (160 mL), and Pd / C (510 mg) was added to displace the hydrogen. The reaction was stirred at room temperature for 20 hours. After the reaction, the reaction solution was filtered with MeOH and concentrated under reduced pressure at 40°C to obtain a yellow-brown oily liquid compound (2.1 g, crude product). MS (ESI, m / z) 151.1 [M+H] + .
[0230] Step 6: Synthesis of Intermediate A7
[0231] Methods: Under a nitrogen atmosphere, A6 (1.0 g, 6.67 mmol) was dissolved in DMF (20 mL). SM2 (1.85 g, 7.37 mmol) and K2CO3 (2.76 g, 20 mmol) were added sequentially to replace the nitrogen atmosphere. The reaction was stirred at 80°C for 24 hours. After completion of the reaction, water (60 mL) was added and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phase was washed with saturated NaCl solution, dried over anhydrous Na2SO4, and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE:EA = 5:1, V / V) to obtain a white solid compound (1.52 g, yield 71.3%). MS (ESI, m / z) 322.2 [M+H] + .
[0232] Step 7: Synthesis of Intermediate A8
[0233] Methods: A7 (1.52 g, 4.75 mmol) was dissolved in DCM (20 mL), and TFA (4 mL) was added. The reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was poured into a 2 M NaOH solution to quench the reaction mixture. NaOH was added to adjust the pH to 10, and the mixture was extracted with DCM:MeOH = 10:1 (50 mL x 3). The organic phase was washed with saturated NaCl solution, dried over anhydrous Na2SO4, and concentrated under reduced pressure at 40°C to obtain a yellow oily liquid compound (740 mg, crude product). MS (ESI, m / z) 222.1 [M+H] + .
[0234] Step 8: Synthesis of Intermediate A9
[0235] Methods: Int 1 (350 mg, 1.54 mmol) was dissolved in DMF (10 mL). HATU (660 mg, 1.74 mmol) and TEA (380 mg, 3.76 mmol) were slowly added, followed by stirring at room temperature for 5 min. A8 (740 mg) was then added and stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was poured into H2O (50 mL) and extracted with ethyl acetate (30 mL × 3). The organic phase was washed with saturated NaCl solution, dried over anhydrous Na2SO4, and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE:EA = 1:1, V / V) to obtain the compound as a yellow oily liquid (800 mg, yield 55.6%). MS (ESI, m / z) 431.3 [M+H] + .
[0236] Step 9: Synthesis of BX20-7-Q17
[0237] Methods: A9 (800 mg, 1.86 mmol) was dissolved in DCM (10 mL), and TFA (2 mL) was slowly added. The reaction was stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was quenched by NaOH solution and extracted with DCM:MeOH = 20:1 (50 mL × 3). The organic phase was washed with saturated NaCl solution, dried over anhydrous Na2SO4, and concentrated under reduced pressure at 40°C. The product was purified by preparative chromatography (ammonia system, column: Waters xbridge 150×25 mm 10 μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water ((0.05% ammonia hydroxide v / v), B: acetonitrile; elution gradient: phase B 17% to 47% over 12 min). The product was lyophilized to obtain a white solid powder (123 mg, yield: 20.0%). MS (ESI, m / z) 331.2 [M+H] + .
[0238] 1 H NMR (400MHz, DMSO-d6) δ = 7.75-7.60 (m, 1H), 7.19-7.15 (m, 2H), 6.93-6.84 (m, 2H), 4.90 (dd, J = 8.0Hz, J = 8.0Hz, 2H), 4.68 (dd, J=8.0Hz, J=8.0Hz,2H),4.44-4.36(m,1H),3.99(s,2H),3.44-3.22(m,1H),2.84-2.69(m,3H),1.69-1.44(m,3H),1.28(s,6H).
[0239] Example 8:
[0240] Synthesis of BX20-7-Q18
[0241] Step 1: Synthesis of intermediate A1
[0242] Method: Dissolve BnOH (2.16 g, 20 mmol) in DMF (20 mL). Slowly add NaH (800 mg, 20 mmol) under ice-cooling. After stirring for half an hour, add A0 (3.0 g, 13.4 mmol). Stir the reaction mixture at room temperature for 3 hours. After completion, quench with saturated ammonium chloride solution, extract with EA, wash with concentrated brine, and dry over anhydrous sodium sulfate. The organic phase is concentrated under reduced pressure and purified by column chromatography to yield A1 (3.68 g, 88.0%) as a colorless oil. MS (ESI, m / z) 312 [M+H] + .
[0243] Step 2: Synthesis of intermediate A2
[0244] The synthetic route is shown below:
[0245] Method: 2-Pyridinecarboxylic acid (147 mg, 1.18 mmol), CuI (225 mg, 1.18 mmol), and Cs2CO3 (11.8 g, 36.4 mmol) were added to a dry three-necked flask. The reaction system was purged with nitrogen three times. A1 (3.68 g, 11.8 mmol) was dissolved in 1,4-dioxane (12 mL) and added to the flask. Diethyl malonate (3.7 mL) was then added to the flask. The reaction mixture was stirred at 50°C for 20 hours. After the reaction, the mixture was cooled to room temperature and filtered through Celite. The filtrate was directly concentrated and purified by column chromatography (PE:EA = 3:1, V / V) to afford A2 (3.95 g, crude product, containing diethyl malonate) as a colorless oil. MS (ESI, m / z) 344 [M+H] + .
[0246] Step 3: Synthesis of Intermediate A3
[0247] The synthetic route is shown below:
[0248] Method: LiAlH4 (1.3 g, 34.1 mmol) was added to anhydrous THF (30 mL). A solution of A2 in THF (3.95 g, crude product, 10 mL) was slowly added dropwise under ice-cooling. The reaction mixture was stirred at room temperature for 12 hours. After completion of the reaction, H2O (1.3 mL), NaOH solution (15%, 1.3 mL), and H2O (3.9 mL) were added sequentially under ice-cooling. The mixture was stirred thoroughly and filtered through Celite. The filtrate was directly concentrated and purified by column chromatography (PE:EA = 1:1, V / V) to afford A3 (330 mg, 11.0%) as a white solid. MS (ESI, m / z) 260 [M+H] + .
[0249] Step 4: Synthesis of intermediate A4
[0250] The synthetic route is shown below:
[0251] Method: Under a nitrogen atmosphere, A3 (300 mg, 1.16 mmol) was added to anhydrous THF (15 mL). n-BuLi (0.5 mL, 2.5 M) was slowly added dropwise at 0°C. The reaction mixture was stirred at this temperature for 30 min. TsCl (229 mg, 1.2 mmol) in THF (3 mL) was then added dropwise. The mixture was stirred at 0°C for 1 hour, and n-BuLi (0.5 mL, 2.5 M) was added. After the addition, the reaction mixture was stirred at 60°C for 6 hours. After completion of the reaction, the reaction mixture was quenched by pouring into saturated ammonium chloride, extracted with EA, washed with brine, dried over anhydrous sodium sulfate, and the organic phase was concentrated under reduced pressure and purified by column chromatography (PE:EA = 3:1, V / V) to afford A4 (200 mg, 71.2%) as a white solid. MS (ESI, m / z) 242 [M+H] + .
[0252] Step 5: Synthesis of Intermediate A5
[0253] The synthetic route is shown below:
[0254] Method: Dissolve A4 (200 mg, 0.83 mmol) in MeOH (10 mL), add Pd / C (10%, 40 mg), replace the hydrogen atmosphere with a hydrogen balloon, and stir the reaction system at room temperature for 12 hours. After completion of the reaction, filter the reaction mixture through celite and concentrate under reduced pressure to obtain A5 (120 mg, crude) as a white solid. MS (ESI, m / z) 152 [M+H] + .
[0255] Step 6: Synthesis of intermediate A6
[0256] The synthetic route is shown below:
[0257] Method: A5 (2.6 g, 17.2 mmol) was dissolved in DMF (50 mL), and B1 (4.7 g, 18.9 mmol) and K2CO3 were added. The reaction system was stirred at 80°C for 12 hours. After completion of the reaction, the reaction solution was filtered through celite, extracted with EA, washed with brine, and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure and purified by column chromatography (PE:EA = 3:1, V / V) to afford A6 (1.1 g, 19.8%) as a yellow solid. MS (ESI, m / z) 323 [M+H] + .
[0258] Step 7: Synthesis of Intermediate A7
[0259] The synthetic route is shown below:
[0260] Method: A6 (1.1 g, 3.4 mmol) was dissolved in DCM (25 mL), and TFA (4 mL) was added. The reaction system was stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was poured into saturated sodium bicarbonate solution for quenching, extracted with DCM / MeOH (20:1), washed with concentrated brine, dried over anhydrous sodium sulfate, and the organic phase was concentrated under reduced pressure to obtain A7 (450 mg, crude) as a yellow oil. MS (ESI, m / z) 223 [M+H] + .
[0261] Step 8: Synthesis of Intermediate A8
[0262] Methods: Compound A7 (450 mg, crude product, approximately 2 mmol) was dissolved in DMF (10 mL). HATU (836 mg, 2.2 mmol) and TEA (666 mg, 6.6 mmol) were added sequentially. The mixture was stirred for 10 min, followed by the addition of Int 1 (500 mg, 2.2 mmol). The reaction mixture was stirred at room temperature for 1 h. After completion, the reaction mixture was quenched by pouring into water, extracted with EA, washed with concentrated brine, and dried over anhydrous sodium sulfate. The organic phase was concentrated and purified by column chromatography (PE:EA = 1:1, V / V) to afford A8 (450 mg, 52.0%) as a yellow oil. MS (ESI, m / z) 432 [M+H] + .
[0263] Step 9: Synthesis of BX20-7-Q18
[0264] Methods: A8 (450 mg, 1.04 mmol) was dissolved in DCM (10 mL), and TFA (2 mL) was added. The reaction system was stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was poured into saturated sodium bicarbonate solution for quenching, extracted with DCM / MeOH (20:1), washed with brine, and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure and purified by preparative chromatography (NH4HCO3 system, column: Waters xBridge 150×25 mm 10 μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (10 mM NH4HCO3), B: acetonitrile; elution gradient: phase B from 12% to 42% over 15 min). After lyophilization, BX20-7-Q18 (61 mg, 17.7%) was obtained as a white solid powder. MS (ESI, m / z) 332 [M+H] + .
[0265] 1H NMR (400MHz, DMSO-d6) δ = 7.99 (dd, J = 5.2Hz, 1.6Hz, 1H), 7.72 (brs, 1H), 7.59 (d ,J=7.2Hz,1H),6.95(dd,J=7.2Hz,4.8Hz,1H),4.88(dd,J=8.4Hz,6.0Hz,2H),4. 69(dd,J=7.6Hz,6.4Hz,2H),4.37-4.29(m,1H),4.25(s,2H),3.43-3.21(m,2H) ,2.81-2.70(m,2H),1.68(brs,1H),1.58(brs,1H),1.46(brs,1H),1.27(s,6H).
[0266] Example 9:
[0267] Synthesis of BX20-7-Q20
[0268] Step 1: Synthesis of intermediate S2
[0269] The synthetic route is shown below:
[0270] Method: Compound SM1 (3.0 g, 34.5 mmol) was dissolved in THF (50 mL). NaH (60%, 1.52 g, 38.0 mmol) was added portionwise at 0°C. The mixture was stirred for 30 min, followed by the addition of S1 (3.0 g, 13.8 mmol). The reaction mixture was stirred at room temperature for 1 h. After completion of the reaction, the mixture was quenched with saturated ammonium chloride solution, extracted with EA, and washed with brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield S2 (4.2 g, crude) as a yellow solid. MS (ESI, m / z) 270, 272 [M+H] + .
[0271] Step 2: Synthesis of intermediate S3
[0272] The synthetic route is shown below:
[0273] Methods: S2 (2.2 g, 8.1 mmol) was dissolved in DMF (30 mL), and PdCl2(PPh3)2 (280 mg, 0.4 mmol), CuI (152 mg, 0.8 mmol), and TEA (2.4 g, 24.0 mmol) were added sequentially. After displacing the nitrogen atmosphere, SM2 (10.5 mL, 1.0 M in DMF) was added, and the reaction mixture was stirred at 60°C for 10 h. After completion of the reaction, the mixture was filtered through celite and washed with EA. The filtrate was collected and extracted with saturated brine. The organic phase was dried, concentrated under reduced pressure, and purified by column chromatography (PE:EA = 1:1, V / V) to afford S3 (400 mg, 21.6%) as a yellow-brown oil. MS (ESI, m / z) 230 [M+H] + .
[0274] Step 3: Synthesis of intermediate S4
[0275] The synthetic route is shown below:
[0276] Methods: Compound Int 1 (300 mg, 1.3 mmol) was dissolved in DMF (10 mL). HATU (570 mg, 1.5 mmol) and TEA (450 mg, 4.5 mmol) were added sequentially. The reaction mixture was stirred for 5 minutes before S3 (343 mg, 1.5 mmol) was added. The reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was poured into water to quench the reaction, extracted with EA, washed with concentrated brine, and dried over anhydrous sodium sulfate. The organic phase was concentrated and purified by column chromatography (PE:EA = 1:1, V / V) to obtain compound S4 (280 mg, 49.2%) as a yellow solid. MS (ESI, m / z) 439 [M+H] + .
[0277] Step 4: Synthesis of BX20-7-Q20
[0278] The synthetic route is shown below:
[0279] Methods: Compound S4 (280 mg, 0.64 mmol) was dissolved in DCM (8 mL), and TFA (1 mL) was added. The reaction mixture was stirred at 25°C for 1 h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure at 40°C. The residue was purified by preparative separation (formic acid system, column: Phenomenex luna C18 150×25mm 10μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (0.225% FA), B: acetonitrile; elution gradient: phase B from 7% to 27% over 12 min). After lyophilization, BX20-7-Q20 (60 mg, 27.7%) was obtained as a light yellow powder. MS (ESI, m / z) 339 [M+H] + .
[0280] 1 H NMR (400MHz, DMSO-d6) δ = 8.55 (d, J = 2.0Hz, 1H), 8.19 (d, J = 2.4Hz, 1H), 7.76 (s, 1H), 4 .44(s,2H),3.01-2.95(m,4H),2.08(s,3H),1.73(s,2H),1.57(brs,1H),1.30(s,6H).
[0281] Example 10:
[0282] Synthesis of BX20-7-Q21
[0283] Step 1: Synthesis of intermediate S2
[0284] The synthetic route is shown below:
[0285] Methods: Compound S1 (2.00 g, 8.97 mmol) was dissolved in DMF (20 mL). PdCl2(PPh3)2 (316 mg, 0.45 mmol), CuI (173 mg, 1.01 mmol), and TEA (2.71 g, 26.83 mmol) were added sequentially. After nitrogen was replaced, compound S0 (710 mg, 10.75 mmol) was added and stirred at 20°C for 5 h. After completion of the reaction, ethyl acetate (50 mL) was added and filtered. Water (60 mL) was added and the mixture was extracted with ethyl acetate (25 mL x 3). The organic phase was washed with saturated NaCl solution, dried, and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE / EA = 5 / 1, V / V) to obtain compound S2 (1.40 g, 96.9% yield) as a yellow oily liquid. MS (ESI, m / z) 162.0 [M+H] + .
[0286] Step 2: Synthesis of intermediate S3
[0287] Methods: Compound Int S1 (1.93 g, 21.6 mmol) was dissolved in 1,4-dioxane (40 mL). NaH (60%, 884 mg, 22.1 mmol) was added and stirred at room temperature for 10 minutes. S2 (1.4 g, 8.7 mmol) was then added and the reaction was stirred at 100°C for 1 hour. After completion of the reaction, the reaction solution was quenched by adding saturated NH4Cl solution dropwise. DCM (30 mL x 3) was added for extraction and washed with saturated NaCl solution. The organic phase was dried and concentrated under reduced pressure at 40°C to obtain compound S3 (2.44 g, crude) as a reddish-brown oil. MS (ESI, m / z) 231.1 [M+H] + .
[0288] Step 3: Synthesis of intermediate S4
[0289] Method: Int 1 (300 mg, 1.32 mmol) was dissolved in anhydrous DMF (10 mL), and HATU (752 mg, 1.98 mmol) and TEA (400 mg, 3.96 mmol) were added. The reaction mixture was stirred at room temperature for 5 minutes, and then S3 (651 mg, crude product) was added. The reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was extracted with ethyl acetate, washed with brine, and dried over anhydrous sodium sulfate. The residue was concentrated and purified by column chromatography (PE:EA = 2:1, V / V) to obtain S4 (610 mg, 70.1% yield) as a yellow oil. MS (ESI, m / z) 440.3 [M+H] + .
[0290] Step 4: Synthesis of intermediate BX20-7-Q21
[0291] Methods: S4 (610 mg, 1.39 mmol) was dissolved in DCM (15 mL) and TFA (3 mL) was added dropwise. The reaction was stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was concentrated, water (20 mL) and 1 M NaOH (10 mL) were added to adjust the pH to 9-10, and the mixture was extracted with DCM:MeOH = 20:1 (20 mL × 3). The mixture was washed with brine, dried, and concentrated. The mixture was purified by preparative chromatography (ammonium bicarbonate system, column: Waters xbridge 150×, 25 mm 10 μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (10 mM NH4HCO3), B: acetonitrile; elution gradient: phase B from 17% to 47% over 15 min) and lyophilized to obtain BX20-7-Q21 (150 mg, yield: 31.8%) as a white powder. MS (ESI, m / z) 340.2 [M+H] + .
[0292] 1 H NMR (400MHz, DMSO-d6) δ = 8.02 (dd, J = 5.2Hz, J = 4.8Hz, 1H), 7.67 (dd, J = 7.2Hz, J = 7.6Hz, 1H), 7.58 (s, 1H), 6.90 (dd, J = 7.2Hz, J = 7.6Hz, 1H), 4.28 ( s,2H),2.84(d,J=10.8Hz,2H),2.69(d,J=11.2Hz,2H),1.62-1.60(m,2H ),1.55-1.49(m,2H),1.30(s,6H),0.91-0.87(m,2H),0.72-0.68(m,2H).
[0293] Example 11:
[0294] Synthesis of BX20-7-Q22
[0295] Step 1: Synthesis of intermediate S2
[0296] The synthetic route is shown below:
[0297] Methods: Compound S1 (2.00 g, 8.97 mmol) was dissolved in DMF (20 mL). PdCl2(PPh3)2 (316 mg, 0.45 mmol), CuI (173 mg, 1.01 mmol), and TEA (2.71 g, 26.83 mmol) were added sequentially. After replacing the nitrogen atmosphere, compound S0 (710 mg, 10.44 mmol) was added and stirred at 20°C for 5 h. After completion of the reaction, ethyl acetate (50 mL) was added, the mixture was filtered, extracted with water, and the organic phase was washed with saturated NaCl solution. The organic phase was dried and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE / EA = 20 / 1, V / V) to obtain compound S2 (1.32 g, 90.3% yield) as a yellow oily liquid. MS (ESI, m / z) 164.1 [M+H] + .
[0298] Step 2: Synthesis of intermediate S3
[0299] Method: Compound Int S1 (1.80 g, 20.22 mmol) was dissolved in 1,4-dioxane (40 mL). NaH (60%, 810 mg, 20.25 mmol) was added and stirred at room temperature for 30 minutes. S2 (1.32 g, 8.1 mmol) was then added and the reaction was stirred at 100°C for 1 hour. After completion of the reaction, the reaction solution was quenched by adding saturated NH4Cl solution dropwise. DCM (30 mL x 3) was added for extraction and washed with saturated NaCl solution. The organic phase was dried and concentrated under reduced pressure at 40°C to obtain compound S3 (2.18 g, crude) as a yellow-brown oil. MS (ESI, m / z) 233.2 [M+H] + .
[0300] Step 3: Synthesis of intermediate S4
[0301] Method: Int 1 (300 mg, 1.32 mmol) was dissolved in anhydrous DMF (10 mL), and HATU (750 mg, 1.98 mmol) and TEA (400 mg, 3.96 mmol) were added. The reaction mixture was stirred at room temperature for 5 minutes, and then S3 (600 mg, crude product) was added. The reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was extracted with ethyl acetate, washed with brine, and dried over anhydrous sodium sulfate. The residue was concentrated and purified by column chromatography (PE:EA = 2:1, V / V) to obtain S4 (638 mg, 79.9% yield) as a yellow oil. MS (ESI, m / z) 442.3 [M+H] + .
[0302] Step 4: Synthesis of intermediate BX20-7-Q21
[0303] Methods: S4 (638 mg, 1.45 mmol) was dissolved in DCM (15 mL) and TFA (3 mL) was added dropwise. The reaction was stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was concentrated, water (20 mL) and NaOH (10 mL, 1 N) were added, and the pH was adjusted to 9-10. The product was purified by preparative chromatography (ammonium bicarbonate system, column: Waters xbridge 150×, 25 mm 10 μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (10 mM NH4HCO3), B: acetonitrile; elution gradient: phase B from 20% to 50% over 12 min). After lyophilization, BX20-7-Q22 (165 mg, yield: 33.4%) was obtained as a white powder. MS (ESI, m / z) 342.2 [M+H] + .
[0304] 1 H NMR (400MHz, DMSO-d6) δ = 8.04 (dd, J = 4.8, J = 5.2, 1H), 7.67 (dd, J = 7.2Hz, J = 7.6Hz, 1H), 7.57 (s, 1H), 6.91 (dd, J = 7.2Hz, J=7.6Hz,1H),4.29(s,2H),3.46-3.43(m,1H),2.84-2.68(m,5H),1.61-1.48(m,3H),1.32(s,6H),1.20(d,J=6.8Hz,6H).
[0305] Example 12:
[0306] Synthesis of BX20-7-Q23
[0307] Step 1: Synthesis of intermediate S2
[0308] The synthetic route is shown below:
[0309] Methods: Compound S1 (2 g, 8.97 mmol) was dissolved in 10 mL of DMF, and PdCl2(PPh3)2 (63 mg, 0.09 mmol), CuI (34 mg, 0.18 mmol), Et3N (2.27 g, 22.42 mol), and SO (830 mg, 9.87 mol) were added sequentially. The reaction mixture was stirred at 60°C for 16 h. After completion, the reaction mixture was slowly added to a saturated aqueous solution of NH4Cl to quench the reaction. The mixture was extracted with EA, washed with a saturated aqueous solution of NaCl, and dried over anhydrous Na2SO4. The organic phase was concentrated under reduced pressure and purified by column chromatography (PE:EA = 10:1) to afford compound S2 (1.6 g, 99.38%) as a yellow oil. MS (ESI, m / z) 180 [M+H] + .
[0310] Step 2: Synthesis of S3
[0311] The synthetic route is shown below:
[0312] Methods: Compound S2 (1.4 g, 7.81 mmol) was dissolved in 20 mL of DCM. After replacing the nitrogen, the system was cooled to -78°C and DAST (1.32 g, 8.13 mmol) was slowly added dropwise. The reaction mixture was stirred at -78°C for 2 h. After completion of the reaction, the reaction mixture was warmed to room temperature and slowly added to water to quench the reaction. The mixture was extracted with DCM, washed with saturated aqueous NaCl, and dried over anhydrous Na2SO4. The organic phase was concentrated under reduced pressure to yield compound S3 (800 mg, crude) as a brown solid. MS (ESI, m / z) 182 [M+H]+.
[0313] Step 3: Synthesis of S4
[0314] The synthetic route is shown below:
[0315] Method: Int S1 (1.03 g, 11.6 mmol) was dissolved in 14 mL of 1,4-dioxane. NaH (479 mg, 12 mmol) was added, and the reaction mixture was stirred at 25°C for 15 min. S3 (700 mg, 3.86 mmol) was then added, and the reaction mixture was stirred at 100°C for 1 h. After completion of the reaction, the reaction mixture was slowly added to a saturated aqueous solution of NH4Cl to quench the reaction. The mixture was extracted with EA, washed with a saturated aqueous solution of NaCl, dried over anhydrous Na2SO4, and the organic phase was concentrated under reduced pressure to obtain compound S4 (820 mg, crude) as a yellow oil. MS (ESI, m / z) 251 [M+H] + .
[0316] Step 4: Synthesis of S6
[0317] The synthetic route is shown below:
[0318] Method: S5 (422 mg, 1.86 mmol) was dissolved in 8 mL of DMF. HATU (771 mg, 2.03 mmol) and TEA (513 mg, 5.07 mmol) were added sequentially. After stirring for 15 min, S4 (470 mg, 1.69 mmol) was added. The reaction mixture was stirred at 25°C for 1 h. After completion of the reaction, the reaction solution was added dropwise to ice water, extracted with EA, washed with saturated aqueous NaCl, and dried over anhydrous Na2SO4. The organic phase was concentrated under reduced pressure and purified by column chromatography (PE:EA = 1:1) to afford S6 (570 mg, 73.40%) as a yellow oil. MS (ESI, m / z) 460 [M+H] + .
[0319] Step 5: Synthesis of BX20-7-Q23
[0320] The synthetic route is shown below:
[0321] Methods: Compound S6 (510 mg, 1.11 mmol) was dissolved in 10 mL of DCM. After adding 2.5 mL of TFA, the reaction mixture was stirred at 25°C for 0.5 h. After completion of the reaction, the reaction mixture was added dropwise to 30 mL of saturated aqueous NaHCO₃ to a pH > 7. The mixture was then extracted with DCM, washed with saturated aqueous NaCl, and dried over anhydrous Na₂SO₄. The organic phase was concentrated under reduced pressure and purified by preparative chromatography (normal phase, Welch Ultimate XB-SiOH 250×70 10 μm column; flow rate: 140 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phases: Hexane A, EtOH B; elution gradient: 5% to 45% phase B over 15 min) to afford compound BX20-7-Q23 (73 mg, 18.30%) as a white solid. MS (ESI, m / z) 360 [M+H] + .
[0322] 1H NMR (400MHz, DMSO-d6) δ=1.21(brs,1H),1.32(s,6H),1.48(t,J=2.74Hz,1H),1.61(br.s,2H),1.66(s,3H),1.71(s,3H),2.70(d,J=10.56Hz,2H) ,2.83(d,J=10.96Hz,2H),4.32(s,2H),6.98(dd,J=7.43,5.09Hz,1H),7.60(s,1H),7.80(dd,J=7.24,1.37Hz,1H),8.14(dd,J=5.09,1.57Hz,1H).
[0323] Example 13:
[0324] Synthesis of BX20-7-Q24
[0325] Step 1: Synthesis of intermediate S2
[0326] The synthetic route is shown below:
[0327] Method: Compound S1 (3.00 g, 15.00 mmol), PdCl2(PPh3)2 (0.53 g, 0.75 mmol), CuI (0.29 g, 1.50 mmol), Et3N (4.56 g, 45.00 mmol), and DMF (20 mL) were added sequentially. The N2 atmosphere was replaced, and SO (1.20 g, 18.00 mmol) was added. The reaction mixture was stirred at 60°C for 1 h. After completion of the reaction, the mixture was filtered through Celite and washed with EA. The filtrate was collected and extracted with saturated brine. The organic phase was dried. The residue was concentrated under reduced pressure and purified by column chromatography (PE:EA = 5:1, V / V) to afford compound S2 (1.85 g, 66.7%) as a brown oil.
[0328] Step 2: Synthesis of intermediate S3
[0329] The synthetic route is shown below:
[0330] Method: Compound Int S1 (1.44 g, 16.20 mmol) was dissolved in 1,4-dioxane (35 mL). NaH (0.67 g, 16.70 mmol) was added portionwise. After stirring for 30 min, S2 (1.00 g, 5.40 mmol) was added. The reaction mixture was heated to 100°C and stirred for 1 h. After completion of the reaction, the reaction mixture was poured into saturated ammonium chloride solution for quenching, extracted with DCM, and the organic phase was dried and concentrated under reduced pressure to obtain compound S3 (0.79 g, 3.10 mmol) as a brown solid. MS (ESI, m / z) 255 [M+H]+ .
[0331] Step 3: Synthesis of intermediate S4
[0332] The synthetic route is shown below:
[0333] Method: Compound Int S2 (0.40 g, 1.80 mmol) was dissolved in DMF (10 mL) and stirred until clear. HATU (0.87 g, 2.30 mmol) and TEA (0.45 g, 4.50 mmol) were added sequentially and stirred for 10 min. S3 (0.79 g, 3.10 mmol) was then added and the reaction mixture was stirred at 25°C for 1 h. After completion of the reaction, the reaction mixture was quenched by adding ice water, extracted with EA, washed with brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (PE:EA = 1:1, V / V) to afford compound S4 (0.80 g, 93.2%) as a colorless oil. MS (ESI, m / z) 464 [M+H] + .
[0334] Step 4: Synthesis of BX20-7-Q24
[0335] The synthetic route is shown below:
[0336] Methods: Compound S4 (0.80 g, 1.70 mmol) was dissolved in anhydrous DCM (10 mL) and stirred until clear. TFA (3 mL) was added, and the reaction mixture was stirred at 25°C for 3 h. After completion of the reaction, the reaction mixture was quenched by adding ice water, extracted with EA, washed with brine, dried over anhydrous sodium sulfate, concentrated, and purified by preparative chromatography (NH4HCO3 system, column: Waters Xbridge 150×, 25 mm 10 μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (10 mM NH4HCO3), B: acetonitrile; elution gradient: phase B from 12% to 45% over 12 min) to afford compound BX20-7-Q24 (125 mg, 20.3%) as a white solid. MS (ESI, m / z) 364 [M+H] + .
[0337] 1H NMR (400MHz, DMSO-d6) δ=7.71-7.65(m,2H),7.62(s,1H),7.09-7.06(d,J=8.4Hz,1H),4.13(s,1H),2.84-2.81(d,J=11.2Hz,2H),2.71 -2.68(d,J=11.2Hz,2H),1.61-1.59(m,2H),1.55-1.49(m,1H),1.47-1.41(m,1H),1.31(s,6H),0.92-0.87(m,2H),0.72-0.68(m,2H).
[0338] Example 14:
[0339] Synthesis of BX20-7-Q25
[0340] Step 1: Synthesis of intermediate S4
[0341] Methods: Compound Int1 (340 mg, 1.50 mmol) was dissolved in DMF (10 mL). HATU (625 mg, 1.64 mmol) and TEA (700 mg, 6.93 mmol) were slowly added, followed by stirring at room temperature for 5 min. S3 (500 mg, 1.64 mmol, hydrochloride) was then added and the reaction stirred at room temperature for 1 hour. After completion, the reaction solution was quenched by pouring into H2O (100 mL), extracted with EA (50 mL × 3), and washed with saturated NaCl solution. The organic phase was dried and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE:EA = 1:1, V / V) to afford S4 (600 mg, 83.6% yield) as a yellow solid. MS (ESI, m / z) 478, 480 [M+H] + .
[0342] Step 2: Synthesis of intermediate S5
[0343] Methods: S4 (600 mg, 1.25 mmol) was dissolved in DMF (10 mL). PdCl2(PPh3)2 (42 mg, 0.06 mmol), CuI (23 mg, 0.12 mmol), and TEA (380 mg, 3.75 mmol) were added sequentially. After nitrogen was replaced, SO (164 mg, 2.5 mmol) was added. The reaction mixture was stirred at 70°C for 8 hours. After completion of the reaction, the reaction mixture was poured into H2O (100 mL) for quenching and extracted with ethyl acetate (50 mL × 3). The reaction mixture was washed with saturated NaCl solution, dried over anhydrous Na2SO4, and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE:EA = 2:1, V / V) to obtain S5 (190 mg, 31.7% yield) as a yellow solid. MS (ESI, m / z) 480 [M+H] + .
[0344] Step 3: Synthesis of intermediate BX20-7-Q25
[0345] Methods: S5 (190 mg, 0.396 mmol) was dissolved in DCM (5 mL), and TFA (1.5 mL) was added. The reaction was stirred at room temperature for 1 h. After the reaction, the pH was adjusted to 9-10 with NaOH solution, and the mixture was extracted with DCM / MeOH (20:1). The organic phase was washed with saturated NaCl solution, dried over anhydrous Na2SO4, and concentrated under reduced pressure at 40°C. The product was purified by preparative chromatography (ammonia system, column: Waters xbridge 150×, 25 mm 10 μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelength: 220 nm and 254 nm; mobile phase: A: water ((0.05% ammonia hydroxide v / v), B: acetonitrile; elution gradient: phase B from 12% to 42% in 12 min) to give BX20-7-Q25 as a white solid (71 mg, yield: 47.2%). MS (ESI, m / z) 380 [M+H] + .
[0346] 1H NMR (400MHz, DMSO-d6) δ = 7.80 (d, J = 2.4, 1H), 7.76 (dd, J = 8.4Hz, 2.0Hz, 1H), 7.63 (s, 1H), 7.15 (d, J = 8.4Hz, 1H), 4.80 (dd, J = 8.8Hz, 5.6Hz, 2 H),4.59(dd,J=7.2Hz,5.2Hz,2H),4.18-4.11(m,3H),3.42-3.19(m,1H),2.82-2.67(m,3H),1.66-1.58(m,2H),1.46(brs,1H),1.33(s,6H).
[0347] Example 15:
[0348] Synthesis of BX20-7-Q26
[0349] Step 1: Synthesis of intermediate S2
[0350] Method: S1 (2.0 g, 10.0 mmol) was dissolved in DMF (30 mL), and K2CO3 (4.1 g, 30.0 mmol) and B1 (2.8 g, 11.0 mmol) were added. The reaction was stirred at 80°C for 8 hours. After completion of the reaction, the mixture was filtered, extracted with ethyl acetate, washed with brine, and dried over anhydrous sodium sulfate. The organic phase was concentrated and purified by column chromatography (PE:EA = 3:1, V / V) to obtain S2 (3.3 g, 89%) as a white solid. MS (ESI, m / z) 410 [M+H] + .
[0351] Step 2: Synthesis of intermediate S3
[0352] Method: Dissolve S2 (2.0 g, 5.4 mmol) in DCM (40 mL), add HCl / 1,4-dioxane (13.5 mL, 4 M), and stir at room temperature for 1 hour. After the reaction, the reaction mixture was directly dried to obtain a yellow solid powder S3 (1.7 g, crude product, hydrochloride). MS (ESI, m / z) 269, 271 [M+H] + .
[0353] Step 3: Synthesis of intermediate S4
[0354] Method: Int 1 (681 mg, 3.0 mmol) was dissolved in DMF (30 mL). HATU (1.25 g, 3.3 mmol) and TEA (1.3 g, 13.2 mmol) were added sequentially. The mixture was stirred at room temperature for 10 minutes before S3 (1.0 g, hydrochloride, approximately 3.2 mmol) was added and stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was poured into water to quench, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (PE:EA = 2:1, V / V) afforded S4 (720 mg, 50.1% yield) as a yellow solid. MS (ESI, m / z) 478, 480 [M+H] + .
[0355] Step 4: Synthesis of S5
[0356] Method: Dissolve S4 (720 mg, 1.5 mmol) in DCM (10 mL), add HCl / 1,4-dioxane (4 mL, 4 M), and stir at room temperature for 1 hour. After the reaction, the reaction mixture is directly dried to obtain S5 (650 mg, crude product, hydrochloride) as a yellow oil. MS (ESI, m / z) 378, 380 [M+H] + .
[0357] Step 5: Synthesis of BX20-7-Q26
[0358] The synthetic route is shown below:
[0359] Method: Compound S5 (700 mg, 1.85 mmol) was dissolved in DMF (15 mL), and Pd(PPh3)2Cl2 (56 mg, 0.08 mmol), CuI (31 mg, 0.16 mmol) and Et3N (505 mg, 5 mmol) were added in sequence. After nitrogen was replaced, S6 (310 mg, 3.7 mmol) was added, and the reaction mixture was reacted at 80°C for 12 h. After completion of the reaction, water was added to quench the reaction, followed by extraction with ethyl acetate. The organic phase was dried and concentrated under reduced pressure at 40°C. Purification by column chromatography (DCM:MeOH = 10:1, V / V) afforded 270 mg of a crude yellow oily liquid. This crude product was then purified by preparative chromatography (ammonium bicarbonate system; column: Waters xbridge 150×, 25 mm 10 μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (10 mM NH₄HCO₃), B: acetonitrile; elution gradient: phase B from 15% to 45% over 12 min). After lyophilization, BX20-7-Q26 (100 mg, 14.2%) was obtained as a white solid. MS (ESI, m / z) 382 [M+H] + .
[0360] 1 H NMR (400MHz, DMSO-d6) δ = 7.80-7.72 (m, 2H), 7.58 (s, 1H), 7.12 (d, J = 8.0Hz, 1H), 5.43 (brs, 1H), 4.1 5(s,2H),3.44-3.25(m,1H),2.83-2.68(m,3H),1.73-1.59(m,2H),1.47-1.42(m,7H),1.34(s,6H).
[0361] Example 16:
[0362] Synthesis of BX20-7-Q27
[0363] Step 1: Synthesis of intermediate S5
[0364] The synthetic route is shown below:
[0365] Methods: Compound S4 (500 mg, 1.22 mmol) was dissolved in 5 mL of DMF, and PdCl2(PPh3)2 (43 mg, 0.06 mmol), CuI (23 mg, 0.12 mmol), Et3N (371 mg, 3.67 mol), and SM1 (121 mg, 1.83 mol) were added sequentially. The reaction mixture was stirred at 60°C for 2 h. After completion, the reaction mixture was slowly added to a saturated aqueous solution of NH4Cl to quench the reaction. The mixture was extracted with EA, washed with a saturated aqueous solution of NaCl, and dried over anhydrous Na2SO4. The organic phase was concentrated under reduced pressure and purified by column chromatography (PE:EA = 5:1) to afford compound S5 (300 mg, 70.67%) as a yellow solid. MS (ESI, m / z) 348 [M+H] + .
[0366] Step 2: Synthesis of intermediate S6
[0367] The synthetic route is shown below:
[0368] Method: Compound S5 (300 mg, 0.86 mmol) was dissolved in 6 mL of DCM. After adding 0.6 mL of TFA, the reaction mixture was stirred at 25°C for 0.5 h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to obtain compound S6 (370 mg, crude product) as a brown oil. MS (ESI, m / z) 248 [M+H] + .
[0369] Step 3: Synthesis of intermediate S7
[0370] The synthetic route is shown below:
[0371] Method: Int 1 (299 mg, 1.3 mmol) was dissolved in 6 mL of DMF. HATU (546 mg, 1.4 mmol) and TEA (363 mg, 3.6 mmol) were added sequentially. After stirring for 15 min, S6 (370 mg, 1.2 mmol) was added. The reaction mixture was stirred at 25°C for 1 h. After completion of the reaction, the reaction solution was added dropwise to ice water, extracted with EA, washed with saturated aqueous NaCl, and dried over anhydrous Na2SO4. The organic phase was concentrated under reduced pressure and purified by column chromatography (PE:EA = 4:1) to afford S7 (170 mg, 18.41%) as a yellow oil. MS (ESI, m / z) 457 [M+H] + .
[0372] Step 4: Synthesis of BX20-7-Q27
[0373] The synthetic route is shown below:
[0374] Method: Compound S7 (170 mg, 0.37 mmol) was dissolved in 5 mL of DCM. After adding 0.5 mL of TFA, the reaction mixture was stirred at 25°C for 0.5 h. After completion of the reaction, the reaction solution was added dropwise to 30 mL of saturated aqueous NaHCO₃ to a pH > 7. The mixture was then extracted with DCM, washed with saturated aqueous NaCl, and dried over anhydrous Na₂SO₄. The organic phase was concentrated under reduced pressure and purified by column chromatography (DCM:MeOH = 5:1, V / V) to afford compound BX20-7-Q27 (44 mg, 33.15%) as a yellow solid. MS (ESI, m / z) 360 [M+H] + .
[0375] 1 H NMR (400MHz, DMSO-d6)δ=0.64-0.73(m,2H),0.80-0.92(m,2H),1.21(s,1H),1.31(s,6H),1.45-1.57(m,2H),1.68(brs, 2H),2.80-2.88(m,2H),2.90-2.97(m,2H),4.00(s,2H),6.91(dd,J=9.00,4.70Hz,1H),7.00-7.17(m,2H),7.61(s,1H).
[0376] Example 17:
[0377] Synthesis of BX20-7-Q28
[0378] Step 1: Synthesis of intermediate S5
[0379] The synthetic route is shown below:
[0380] Methods: Compound S4 (600 mg, 1.47 mmol) was dissolved in 6 mL of DMF. PdCl2(PPh3)2 (51 mg, 0.07 mmol), CuI (28 mg, 0.15 mmol), and Et3N (445 mg, 4.40 mol) were added sequentially. After displacing the nitrogen, SM1 (181 mg, 2.20 mol) was added. The reaction mixture was stirred at 60°C for 1 h. After completion of the reaction, the reaction mixture was quenched in water, extracted with EA, washed with saturated aqueous NaCl, and dried over anhydrous Na2SO4. The organic phase was concentrated under reduced pressure and purified by column chromatography (PE:EA = 5:1, V / V) to afford compound S5 (740 mg, 92.59%) as a brownish-yellow solid. MS (ESI, m / z) 364 [M+H] + .
[0381] Step 2: Synthesis of intermediate S6
[0382] The synthetic route is shown below:
[0383] Method: Compound S5 (750 mg, 2.06 mmol) was dissolved in 15 mL of DCM. 3 mL of TFA was added, and the reaction mixture was stirred at room temperature for 0.5 h. After completion of the reaction, the reaction mixture was added dropwise to a KOH aqueous solution until the pH was >8. The mixture was then extracted with a 20:1 ratio of DCM:MeOH, washed with a saturated NaCl aqueous solution, and dried over anhydrous Na2SO4. The organic phase was concentrated under reduced pressure to yield Compound S6 (560 mg, crude) as a yellow-brown oil. MS (ESI, m / z) 264 [M+H] + .
[0384] Step 3: Synthesis of intermediate S7
[0385] The synthetic route is shown below:
[0386] Method: Int 1 (484 mg, 2.13 mmol) was dissolved in DMF (10 mL). HATU (886 mg, 2.32 mmol) and TEA (588 mg, 5.81 mmol) were added sequentially. After stirring for 15 min, S6 (510 mg, 1.94 mmol) was added. The reaction mixture was stirred at 25°C for 1 h. After completion, the reaction mixture was quenched by adding water and extracted with EA. The organic phase was washed with brine, dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by column chromatography (PE:EA = 1:1, V / V) to afford S7 (760 mg, 83.03%) as a colorless oil. MS (ESI, m / z) 473 [M+H] + .
[0387] Step 4: Synthesis of BX20-7-Q28
[0388] The synthetic route is shown below:
[0389] Methods: Compound S7 (760 mg, 1.61 mmol) was dissolved in 15 mL of DCM. After the addition of TFA (3 mL), the reaction mixture was stirred at 25°C for 0.5 h. After completion of the reaction, the reaction mixture was added dropwise to aqueous KOH until the pH was >8, and then extracted with DCM:MeOH (20:1). The organic phase was washed with saturated aqueous NaCl, dried over anhydrous Na2SO4, and concentrated under reduced pressure. Purification by preparative chromatography (NH4 bicarbonate system, column: Waters xbridge 150×, 25 mm 10 μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (10 mM NH4HCO3), B: acetonitrile; elution gradient: phase B from 15% to 45% over 12 min) afforded BX20-7-Q28 (391 mg, 65.28%) as a white solid. MS (ESI, m / z) 373 [M+H] + .
[0390] 1 H NMR (400MHz, DMSO-d6) δ = 7.56 (s, 1H), 7.19-7.09 (m, 2H), 6.98 (dd, J = 9.2Hz, 4.4Hz, 1H), 4.80 (dd, J = 8.4Hz, 5.6Hz, 2H), 4.59 (dd, J = 7.2Hz, 5.2Hz,2H),4.17-4.09(m,1H),4.05(s,2H),3.44-3.25(m,0.6H),2.83-2.67(m,3.4H),1.72-1.58(m,2H),1.48-1.46(m,1H),1.32(s,6H).
[0391] Example 18:
[0392] Synthesis of BX20-7-Q29
[0393] Step 1: Synthesis of intermediate S2
[0394] The synthetic route is shown below:
[0395] Methods: Compound SM1 (917 mg, 10.31 mmol) was dissolved in THF (20 mL). NaH (60%, 453 mg, 11.33 mmol) was added and stirred at room temperature for 0.5 h. S1 (1.0 g, 5.15 mmol) was then added and stirred at room temperature for 1 h. After completion of the reaction, the reaction solution was added dropwise to a saturated NH4Cl solution (100 mL). The mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated NaCl solution, dried, and concentrated under reduced pressure at 40°C to afford compound S2 (1.52 g, crude) as a yellow oil. MS (ESI, m / z) 263.0 [M+H] + .
[0396] Step 2: Synthesis of intermediate S3
[0397] Methods: Compound Int1 (400 mg, 1.76 mmol) was dissolved in DMF (20 mL). HATU (737 mg, 1.94 mmol) and TEA (784 mg, 7.76 mmol) were slowly added, followed by stirring at room temperature for 5 min. S2 (490 mg, 1.86 mmol) was then added and stirred at room temperature for 1 hour. After completion, the reaction solution was quenched by pouring into H2O (100 mL), extracted with EA (50 mL × 3), and washed with saturated NaCl solution. The organic phase was dried and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE:EA = 1:1, V / V) to afford compound S3 (770 mg, 87.6% yield) as a white solid. MS (ESI, m / z) 472.1 [M+H] + .
[0398] Step 3: Synthesis of intermediate S4
[0399] Methods: S3 (770 mg, 1.63 mmol) was dissolved in DMF (10 mL). PdCl2(PPh3)2 (100 mg, 0.14 mmol), CuI (60 mg, 0.32 mmol), and TEA (494 mg, 4.89 mmol) were slowly added in sequence and stirred until uniform. SM2 (1 M, 2.5 mL, 2.5 mmol) was then added and the reaction was stirred at 60°C for 3 hours. After completion, the reaction solution was quenched by dropwise addition of H2O (100 mL), extracted with ethyl acetate (50 mL × 3), washed with saturated NaCl solution, dried over anhydrous Na2SO4, and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE:EA = 2:1, V / V) to obtain S4 (460 mg, 65.4%) as a yellow-brown solid. MS (ESI, m / z) 432.2 [M+H] + .
[0400] Step 4: Synthesis of intermediate BX20-7-Q29
[0401] Methods: S4 (460 mg, 1.07 mmol) was dissolved in DCM (10 mL), and TFA (3 mL) was added. The reaction was stirred at 30°C for 1 h. After completion of the reaction, the pH was adjusted to 9-10 with NaOH, and the mixture was extracted with DCM:MeOH (20:1). The organic phase was washed with saturated NaCl solution, dried over anhydrous Na2SO4, and concentrated under reduced pressure at 40°C. Purification by preparative chromatography (column: Waters xbridge 150×, 25 mm 10 μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (10 mM NH4HCO3), B: acetonitrile; elution gradient: phase B from 12% to 42% over 12 min) gave BX20-7-Q29 (138 mg, yield: 39.1%) as a chromatic solid. MS (ESI, m / z) 332.2 [M+H] + .
[0402] 1 H NMR (400MHz, DMSO-d6) δ = 8.04 (d, J = 2.8, 1H), 7.74-7.58 (m, 2H), 4.31 (s, 2H), 3.46-2.69 (m, 4H), 2.07 (s, 3H), 1.77-1.43 (m, 3H), 1.29 (s, 6H).
[0403] Example 19:
[0404] Synthesis of BX20-7-Q30
[0405] Step 1: Synthesis of intermediate S2
[0406] Method: Dissolve S1 (2.5 g, crude) in DMF (25 mL), add K2CO3 (4.1 g, 29.7 mmol) and A1 (2.1 g, 9 mmol), and stir at 80°C for 12 hours. After completion of the reaction, quench with water, extract with ethyl acetate, wash with brine, dry over anhydrous sodium sulfate, and concentrate to obtain a yellow solid S2 (4.0 g, crude). MS (ESI, m / z) 410 [M+H] + .
[0407] Step 2: Synthesis of intermediate S3
[0408] The synthetic route is shown below:
[0409] Methods: Compound S2 (2.8 g, crude, approximately 6.8 mmol), Pd(PPh3)2Cl2 (140 mg, 0.2 mmol), Et3N (3.4 g, 34 mmol), and CuI (114 mg, 0.6 mmol) were added sequentially to DMF (15 mL). After nitrogen displacement, A2 (1.33 g, 13.6 mmol) was added, and the reaction mixture was incubated at 60°C for 2 h. After completion, the reaction was quenched with water and extracted with ethyl acetate. The organic phase was dried and concentrated under reduced pressure at 40°C to yield a black oily liquid S3 (3.0 g, crude). MS (ESI, m / z) 380 [M+H] + .
[0410] Step 3: Synthesis of intermediate S4
[0411] Method: Compound S3 (3.0 g, crude product, approximately 7.5 mmol) was dissolved in MeOH (24 mL) and K2CO3 (1.1 g, 8 mmol) was added. The reaction mixture was stirred at room temperature for 1 h. After completion of the reaction, the mixture was filtered, concentrated under reduced pressure, and purified by column chromatography (PE:EA = 3:1, V / V) to afford S4 (1.0 g, 43.3%) as a yellow solid. MS (ESI, m / z) 308 [M+H] + .
[0412] Step 4: Synthesis of Intermediate S5
[0413] Method: Dissolve S4 (1.0 g, 3.2 mmol) in anhydrous DCM (15 mL) and add TFA (3 mL) dropwise. Stir the reaction at room temperature for 1 hour. After the reaction is complete, the reaction solution is directly concentrated to obtain a brown oily liquid S5 (1.0 g, crude product). MS (ESI, m / z) 208 [M+H] + .
[0414] Step 5: Synthesis of Intermediate S6
[0415] Method: Int 1 (681 mg, 3.0 mmol) was dissolved in DMF (15 mL). HATU (1.17 mg, 3 mmol) and TEA (909 mg, 9 mmol) were added sequentially. The mixture was stirred at room temperature for 10 minutes before S5 (1.0 g, crude product, approximately 3 mmol) was added and stirred at room temperature for 1 hour. The reaction mixture was quenched by pouring into water, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (PE:EA = 3:1, V / V) afforded S6 (700 mg, 56.0%) as a yellow oil. MS (ESI, m / z) 417 [M+H] + .
[0416] Step 6: Synthesis of BX20-7-Q30
[0417] Methods: S6 (700 mg, 1.7 mmol) was dissolved in DCM (10 mL) and TFA (2 mL) was added dropwise. The reaction was stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was added to water, the pH was adjusted to 9-10, and the mixture was extracted with DCM / MeOH (10 / 1). The mixture was washed with brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure and purified by preparative chromatography (NH4HCO3 system, column: Waters xbridge 150×25 mm 10 μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (10 mM NH4HCO3), B: acetonitrile; elution gradient: phase B from 15% to 45% over 12 min) to afford BX20-7-Q30 (98 mg, 18.2%) as a pale yellow solid. MS (ESI, m / z) 317 [M+H] + ;
[0418] 1 H NMR (400MHz, DMSO-d6) δ=7.77-7.56(m,1H),7.24(dd,J=8.8Hz,3.2Hz,1H),7.19-7.13(m,1H),6.98(dd,J=9.2Hz,4.8Hz,1H ),4.32(s,1H),4.06(s,2H),3.45-3.23(m,1.4H),2.84-2.67(m,2.6H),1.71-1.58(m,2H),1.46-1.42(m,1H),1.31(s,6H).
[0419] Example 20:
[0420] Synthesis of BX20-7-Q31
[0421] Step 1: Synthesis of intermediate S2
[0422] The synthetic route is shown below:
[0423] Methods: Compound S1 (3.00 g, 15.00 mmol) was dissolved in DMF (15 mL). PdCl2(PPh3)2 (0.31 g, 0.45 mmol), CuI (0.17 g, 0.90 mmol), and Et3N (7.60 g, 75.00 mmol) were added sequentially. After displacing the nitrogen, SO (3.00 g, 30.00 mmol) was added. The reaction mixture was stirred at 80°C for 12 h. After completion, the reaction was quenched with water, extracted with EA, and washed with saturated brine. The organic phase was dried and purified by column chromatography (PE:EA = 10:1, V / V) to afford compound S2 (2.90 g, 88.7%) as a brown oil. MS (ESI, m / z) 218 [M+H] + .
[0424] Step 2: Synthesis of intermediate S3
[0425] The synthetic route is shown below:
[0426] Method: Compound S2 (2.90 g, 13.40 mmol) was dissolved in THF (10 mL), H2O (1 mL) was added, and TBAF (14 mL, 14 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 1 h. After completion of the reaction, the mixture was extracted with EA, washed with brine, and the organic phase was dried, concentrated under reduced pressure, and purified by column chromatography (PE:EA = 20:1, V / V) to afford S3 (1.90 g, 97.7%) as a yellow solid. MS (ESI, m / z) 146 [M+H] + .
[0427] Step 3: Synthesis of intermediate S4
[0428] The synthetic route is shown below:
[0429] Method: Compound Int S1 (3.50 g, 39.30 mmol) was dissolved in 1,4-dioxane (80 mL). NaH (1.60 g, 40.60 mmol) was added portionwise. After stirring for 30 min, S3 (1.90 g, 13.1 mmol) was added. The reaction mixture was stirred at 100°C for 1 h. After completion of the reaction, the reaction mixture was poured into saturated ammonium chloride solution to quench the reaction. The mixture was extracted with DCM, washed with concentrated brine, dried over anhydrous sodium sulfate, and the organic phase was directly concentrated under reduced pressure to obtain compound S4 (2.40 g, crude) as a brown oil. MS (ESI, m / z) 215 [M+H] + .
[0430] Step 4: Synthesis of Intermediate S5
[0431] The synthetic route is shown below:
[0432] Method: Compound Int S2 (0.45 g, 2.00 mmol) was dissolved in DMF (10 mL). HATU (0.99 g, 2.60 mmol) and TEA (0.51 g, 5.00 mmol) were added sequentially. After stirring for 10 min, S4 (0.64 g, 2.4 mmol) was added. The reaction mixture was stirred at 25°C for 1 h. After completion of the reaction, the reaction mixture was quenched by adding ice water, extracted with EA, washed with brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (PE:EA = 1:1, V / V) to afford S5 (0.80 g, 94.5%) as a yellow solid. MS (ESI, m / z) 424 [M+H] + .
[0433] Step 5: Synthesis of BX20-7-Q31
[0434] The synthetic route is shown below:
[0435] Methods: Compound S5 (0.80 g, 1.89 mmol) was dissolved in anhydrous DCM (10 mL), and TFA (3 mL) was added dropwise. The reaction mixture was stirred at 25°C for 1 h. After completion, the reaction mixture was quenched by adding ice water. The pH was adjusted to 9-10 with NaOH solution (1N). The mixture was extracted with DCM, washed with brine, dried over anhydrous sodium sulfate, and concentrated. The mixture was then purified by column chromatography (DCM:MeOH = 20:1, V / V) to afford BX20-7-Q31 (372 mg, 60.7%) as a white solid powder. MS (ESI, m / z) 324 [M+H] + .
[0436] 1 H NMR (400MHz, DMSO-d6) δ = 7.88 (d, J = 2.4Hz, 1H), 7.81-7.77 (m, 1H), 7.69 (s, 1H), 7.16 (d, J = 8.8Hz, 1H), 4.43 (s, 1H) ), 4.20 (s, 2H), 2.86 (d, J = 10.8Hz, 2H), 2.75 (d, J = 10.8Hz, 2H), 1.63-1.61 (m, 2H), 1.47-1.45 (m, 1H), 1.31 (s, 6H).
[0437] Example 21:
[0438] Synthesis of BX20-7-Q32
[0439] Step 1: Synthesis of intermediate S2
[0440] The synthetic route is shown below:
[0441] Methods: Compound SM1 (918 mg, 10.31 mmol) was dissolved in THF (20 mL). NaH (60%, 453 mg, 11.34 mmol) was added and stirred at room temperature for 0.5 h. S1 (1.0 g, 5.15 mmol) was then added and stirred at room temperature for 1 h. After completion of the reaction, the reaction solution was poured into saturated NH4Cl solution (100 mL) and extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated NaCl solution, dried, and concentrated under reduced pressure at 40°C to afford compound S2 (1.63 g, crude) as a yellow oil. MS (ESI, m / z) 263.0 [M+H] + .
[0442] Step 2: Synthesis of intermediate S3
[0443] Methods: Compound Int1 (800 mg, 3.52 mmol) was dissolved in DMF (40 mL). HATU (1.47 g, 3.88 mmol) and TEA (1.55 g, 15.52 mmol) were slowly added, followed by stirring at room temperature for 5 min. S2 (1.02 g, 3.88 mmol) was then added and stirred at room temperature for 1 hour. After completion, the reaction solution was poured into H2O (100 mL) for quenching. The mixture was extracted with EA (50 mL × 3) and washed with saturated NaCl solution. The organic phase was dried and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE:EA = 3:1, V / V) to afford compound S3 (1.56 g, 85.2% yield) as a white solid. MS (ESI, m / z) 472.1 [M+H] + .
[0444] Step 3: Synthesis of intermediate S4
[0445] Methods: S3 (1.56 g, 1.63 mmol) was dissolved in DMF (20 mL). PdCl2(PPh3)2 (70 mg, 0.10 mmol), CuI (50 mg, 0.26 mmol), TEA (1.5 g, 14.85 mmol), and SM2 (946 mg, 6.6 mmol) were slowly added in sequence. The reaction was stirred at 80°C for 5 hours. After completion, the reaction solution was poured into H2O (100 mL) for quenching and extracted with ethyl acetate (50 mL × 3). The reaction solution was washed with saturated NaCl solution, dried over anhydrous Na2SO4, and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE:EA = 3:1, V / V) to obtain compound S4 (1.11 g, 68.5% yield) as a brown oil. MS (ESI, m / z) 489.3 [M+H]+ .
[0446] Step 4: Synthesis of Intermediate S5
[0447] Method: S4 (1.11 g, 2.04 mmol) was dissolved in DCM (10 mL), and TFA (2.5 mL) was added. The reaction was stirred at room temperature for 1 h. After completion of the reaction, the reaction solution was quenched by adding a NaOH solution (1.3 g) dropwise at 0°C. The pH was measured to be 8-9. The solution was extracted three times with DCM:MeOH (10:1). The organic phase was washed with saturated NaCl solution, dried over anhydrous Na2SO4, and concentrated under reduced pressure at 40°C to obtain a brown oil (840 mg, crude product). MS (ESI, m / z) 389.2 [M+H] + .
[0448] Step 5: Synthesis of intermediate BX20-7-Q32
[0449] Methods: S5 (840 mg, 2.15 mmol) was dissolved in THF (4 mL) and H2O (0.4 mL), and TBAF (1.0 M, 4.3 mL) was added. The reaction was stirred at room temperature for 1 h. After the reaction was completed, H2O (100 mL) was added and extracted with ethyl acetate (50 mL × 3). The organic phase was washed with H2O (mL × 3) and saturated NaCl solution, and dried over anhydrous Na2SO4. The organic phase was passed through a silica gel pad with DCM:MeOH = 10:1, concentrated under reduced pressure at 40 ° C, and purified by preparative chromatography (neutral preparative, chromatographic column: Waters xbridge 150 × 25 mm 10 um; flow rate: 25 mL / min; column temperature: room temperature; detection wavelength: 220 nm and 254 nm; mobile phase: A: water (10 mM NH4HCO3), B: acetonitrile; elution gradient: phase B from 17% to 47%, 12 min), freeze-dried to obtain a white solid powder (225 mg, yield 32.9%). MS (ESI, m / z) 317.2 [M+H] + .
[0450] 1 H NMR (400MHz, DMSO-d6) δ = 8.14 (s, 1H), 7.88 (dd, J = 5.6Hz, 1.6Hz, 1H), 7.79-7.61 (m, 1H), 4.52 (s, 1H), 4.32 (s, 2H), 3.4 3-3.25(m,1.4H),2.83(d,J=7.6Hz,1.3H),2.69(d,J=7.2Hz,1.3H),1.73-1.60(m,2H),1.47-1.42(m,1H),1.30(s,6H).
[0451] Example 22:
[0452] Synthesis of BX20-7-Q33
[0453] Step 1: Synthesis of intermediate S2
[0454] The synthetic route is shown below:
[0455] Method: Compound SM1 (3.0 g, 34.5 mmol) was dissolved in THF (50 mL). NaH (60%, 1.52 g, 38.0 mmol) was added portionwise at 0°C. The mixture was stirred for 30 min, followed by the addition of S1 (3.0 g, 13.8 mmol). The reaction mixture was stirred at room temperature for 1 h. After completion of the reaction, the mixture was quenched with saturated ammonium chloride solution, extracted with EA, and washed with brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield S2 (4.2 g, crude) as a yellow solid. MS (ESI, m / z) 270, 272 [M+H] + .
[0456] Step 2: Synthesis of intermediate S3
[0457] Methods: Compound Int 1 (800 mg, 3.52 mmol) was dissolved in DMF (20 mL). HATU (1.47 g, 3.88 mmol) and TEA (1.55 g, 15.52 mmol) were slowly added, followed by stirring at room temperature for 5 min. S2 (1.05 g, 3.88 mmol) was then added and the reaction stirred at room temperature for 1 hour. After completion, the reaction solution was poured into H2O (100 mL) for quenching. The mixture was extracted with EA (50 mL × 3) and washed with saturated NaCl solution. The organic phase was dried and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE:EA = 2:1, V / V) to afford compound S3 (1.73 g, 92.6% yield) as a white solid. MS (ESI, m / z) 479, 481 [M+H] + .
[0458] Step 3: Synthesis of intermediate S4
[0459] Methods: S3 (1.73 g, 3.60 mmol) was dissolved in DMF (9 mL). PdCl2(PPh3)2 (126 mg, 0.18 mmol), CuI (103 mg, 0.54 mmol), and TEA (1.8 g, 18.00 mmol) were slowly added sequentially. After replacing the nitrogen atmosphere, SM2 (705 mg, 7.2 mmol) was added and the reaction was stirred at 80°C for 6 hours. After completion of the reaction, the reaction solution was poured into H2O (100 mL) for quenching, extracted with ethyl acetate (50 mL × 3), and washed with saturated NaCl solution. The organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure at 40°C. The residue was purified by column chromatography (PE:EA = 3:1, V / V) to obtain compound S4 (1.11 g, 62.0% yield) as a brown oil. MS (ESI, m / z) 497.3 [M+H] + .
[0460] Step 4: Synthesis of Intermediate S5
[0461] Method: S4 (1.11 g, 2.24 mmol) was dissolved in DCM (20 mL), and TFA (5 mL) was added. The reaction was stirred at room temperature for 0.3 h. After the reaction, the pH was adjusted to 10 at 0°C, and the mixture was extracted three times with DCM:MeOH = 10:1. The mixture was washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a brown oily compound S5 (700 mg, crude product). MS (ESI, m / z) 397.2 [M+H] + .
[0462] Step 5: Synthesis of intermediate BX20-7-Q33
[0463] Methods: S5 (700 mg, 1.76 mmol) was dissolved in THF (4 mL) and H2O (0.4 mL), and TBAF (1.0 M, 4 mL) was added. The reaction was stirred at room temperature for 0.5 h. After the reaction, the reaction solution was poured into H2O (100 mL) for quenching, and extracted with ethyl acetate (50 mL × 3). The organic phase was washed with H2O (30 mL × 3), washed with saturated NaCl solution, dried over anhydrous Na2SO4, and concentrated under reduced pressure at 40 ° C. It was purified by preparative chromatography (neutral preparative, chromatographic column: Waters xbridge 150 × 25 mm 10 um; flow rate: 25 mL / min; column temperature: room temperature; detection wavelength: 220 nm and 254 nm; mobile phase: A: water (10 mM NH4HCO3), B: acetonitrile; elution gradient: phase B from 17% to 47%, 12 min), lyophilized to obtain a white solid powder BX20-7-Q33 (208 mg, yield 36.3%). MS (ESI, m / z) 325.2 [M+H] + .
[0464] 1 H NMR(400MHz, DMSO-d6)δ=8.65(d,J=2.0,1H),8.36(d,J=2.4,1H),7.65(s,1H),4.60(s,1H),4.47(s,2H),3.45-3.2 6(m,0.8H),2.83(d,J=11.2Hz,1.6H),2.70(d,J=11.2Hz,1.6H),1.60(brs,2H),1.46(t,J=2.8Hz,1H),1.31(s,6H).
[0465] Example 23:
[0466] Synthesis of BX20-7-Q34
[0467] Step 1: Synthesis of intermediate S2
[0468] Method: Dissolve S1 (1.5 g, crude) in DMF (25 mL), add K2CO3 (2.45 g, 17.7 mmol) and A1 (1.63 g, 6.5 mmol), and stir at 80°C for 12 hours. After completion of the reaction, quench with water, extract with ethyl acetate, wash with brine, dry over anhydrous sodium sulfate, and concentrate to obtain a yellow solid S2 (2.8 g, crude). MS (ESI, m / z) 426 [M+H] + .
[0469] Step 2: Synthesis of intermediate S3
[0470] The synthetic route is shown below:
[0471] Method: Compound S2 (2.7 g, 6.3 mmol), Pd(PPh3)2Cl2 (88 mg, 0.126 mmol), Et3N (3.2 g, 31.5 mmol) and CuI (48 mg, 0.252 mmol) were added to DMF (20 mL) in sequence. After nitrogen was replaced, a DMF solution of propyne (1 M, 10 mL, 10 mmol) was added, and the reaction mixture was stirred at 60 °C for 2 h. After the reaction, water was added to quench the reaction, followed by extraction with ethyl acetate. The organic phase was dried, concentrated under reduced pressure, and purified by column chromatography (ammonium bicarbonate, column: Waters xbridge 150×25mm 10um; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (10 mM NH4HCO3), B: acetonitrile; elution gradient: phase B from 12% to 42% over 12 min) to afford S3 (1.85 g, 87.0%) as a yellow-brown solid. MS (ESI, m / z) 338 [M+H] + .
[0472] Step 3: Synthesis of intermediate S4
[0473] Method: Dissolve S3 (1.85 g, 5.5 mmol) in anhydrous DCM (20 mL) and add TFA (4.0 mL) dropwise. Stir the reaction at room temperature for 1 hour. After completion, concentrate the reaction mixture under reduced pressure, add water (20 mL), adjust the pH to 9-10, extract with DCM / MeOH, and concentrate to obtain S4 (1.1 g, crude) as a brown oil. MS (ESI, m / z) 238 [M+H] + .
[0474] Step 4: Synthesis of Intermediate S5
[0475] Method: Int 1 (500 mg, 2.2 mmol) was dissolved in DMF (10 mL). HATU (912 mg, 2.4 mmol) and TEA (727 mg, 7.2 mmol) were added sequentially. The mixture was stirred at room temperature for 5 minutes before S4 (620 mg, crude product, approximately 2.6 mmol) was added. The reaction was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was poured into water to quench, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (PE:EA = 2:1, V / V) afforded S5 as a yellow oil (900 mg, 91.5% yield). MS (ESI, m / z) 447 [M+H] + .
[0476] Step 5: Synthesis of BX20-7-Q34
[0477] Method: S5 (900 mg, 2 mmol) was dissolved in DCM (12 mL) and TFA (2.5 mL) was added dropwise. The reaction was stirred at room temperature for 1 hour. After completion, the pH was adjusted to 9-10, extracted with DCM / MeOH, washed with brine, dried over anhydrous sodium sulfate, and purified by preparative chromatography (PE:EA = 10:1, V / V). After concentration and lyophilization, BX20-7-Q34 (293 mg, 42.2%) was obtained as a light yellow solid. MS (ESI, m / z) 347 [M+H] + .
[0478] 1 H NMR (400MHz, CDCl3) δ = 7.30 (d, J = 2.4Hz, 1H), 7.16 (dd, J = 8.8Hz, 2.8Hz, 1H), 6.79 (d, J = 8.8Hz, 1H), 5 .72(s,1H),4.07(s,2H),3.01-2.93(m,4H),2.09(s,3H),1.83(brs,2H),1.47(s,6H),1.14(brs,1H).
[0479] Example 24:
[0480] Synthesis of BX20-7-Q35
[0481] Step 1: Synthesis of S2
[0482] The synthetic route is shown below:
[0483] Methods: SM1 (2.12 g, 23.76 mmol) was dissolved in 40 mL of THF. NaH (627 mg, 26.14 mmol, 60%) was added in a room temperature water bath. The reaction mixture was stirred at 25°C for 15 min. S1 (2 g, 9.50 mmol) was then added, and the reaction mixture was stirred at 25°C for 1 h. After completion of the reaction, the reaction mixture was slowly added to a saturated aqueous solution of NH4Cl to quench the reaction. The mixture was extracted with EA, washed with a saturated aqueous solution of NaCl, dried over anhydrous Na2SO4, and the organic phase was concentrated under reduced pressure to yield compound S2 (2.4 g, crude) as a yellow oil. MS (ESI, m / z) 279, 281 [M+H] + .
[0484] Step 2: Synthesis of intermediate S3
[0485] The synthetic route is shown below:
[0486] Method: Int 1 (512 mg, 2.25 mmol) was dissolved in 12 mL of DMF. HATU (652 mg, 6.44 mmol) and TEA (652 mg, 6.44 mmol) were added sequentially. After stirring for 5 minutes, S2 (600 mg, 2.15 mmol) was added. The reaction mixture was stirred at 25°C for 1 hour. After completion, the reaction mixture was added dropwise to ice water, extracted with EA, washed with saturated aqueous NaCl, and dried over anhydrous Na2SO4. The organic phase was concentrated under reduced pressure and purified by column chromatography (PE:EA = 2:1, V / V) to afford compound S3 (900 mg, 85.71%) as a yellow solid. MS (ESI, m / z) 488, 490 [M+H] + .
[0487] Step 3: Synthesis of intermediate S4
[0488] The synthetic route is shown below:
[0489] Methods: Compound S3 (900 mg, 1.84 mmol) was dissolved in 9 mL of DMF. PdCl2(PPh3)2 (65 mg, 0.09 mmol), CuI (35 mg, 0.185 mmol), and Et3N (935 mg, 9.21 mol) were added sequentially. After displacing the nitrogen, SM2 (3.7 ml, 3.7 mol, 1 M in DMF) was added. The reaction mixture was stirred at 80°C for 6 h. After completion, the reaction mixture was slowly added to water to quench the reaction. The mixture was extracted with EA, washed with saturated aqueous NaCl, and dried over anhydrous Na2SO4. The organic phase was concentrated under reduced pressure and purified by column chromatography (PE:EA = 3:1, V / V) to afford compound S4 (580 mg, 70.39%) as an orange solid. MS (ESI, m / z) 448 [M+H] + .
[0490] Step 4: Synthesis of BX20-7-Q35
[0491] The synthetic route is shown below:
[0492] Methods: Compound S4 (560 mg, 1.25 mmol) was dissolved in 12 mL of DCM. TFA (2.5 mL) was added and stirred at room temperature for 10 min. After completion of the reaction, the reaction mixture was dropwise added to aqueous NaOH until the pH was >9. The aqueous phase was extracted with DCM, washed with saturated brine, and dried over anhydrous Na2SO4. The organic phase was concentrated under reduced pressure and purified by preparative chromatography (NH4HCO3 system, column: Waters xbridge 150×25 mm 10 μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (10 mM NH4HCO3), B: acetonitrile; elution gradient: phase B from 27% to 37% over 15 min) to afford BX20-7-Q35 (189 mg, 43.46%) as a white solid. MS (ESI, m / z) 348 [M+H] + .
[0493] 1 HNMR (400MHz, DMSO-d6)d=1.30(s,6H),1.46-1.49(m,1H),1.60(brs,2H),2.08(s,3H),2.70(d,J=10.56Hz,2H),2 .83(d,J=10.96Hz,2H),3.43(brs,1H),4.34(s,2H),7.59(s,1H),7.84(d,J=2.35Hz,1H),8.10(d,J=2.35Hz,1H).
[0494] Example 25:
[0495] Synthesis of BX20-7-Q36
[0496] Synthesis of the first intermediate S6
[0497] According to the first to fifth steps of Example 19, intermediate S6 was obtained.
[0498] Step 2: Synthesis of BX20-7-Q36
[0499] Methods: S6 (700 mg, 1.7 mmol) was dissolved in DCM (10 mL) and TFA (2 mL) was added dropwise. The reaction was stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was added to water, the pH was adjusted to 9-10, and the mixture was extracted with DCM / MeOH (10 / 1). The mixture was washed with brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure and purified by preparative chromatography (NH4HCO3 system, column: Waters xbridge 150×25 mm 10 μm; flow rate: 25 mL / min; column temperature: room temperature; detection wavelengths: 220 nm and 254 nm; mobile phase: A: water (10 mM NH4HCO3), B: acetonitrile; elution gradient: phase B from 15% to 45% over 12 min) to afford BX20-7-Q36 (165 mg, 29.0%) as a white solid. MS (ESI, m / z) 335 [M+H] + ;
[0500] 1 H NMR (400MHz, DMSO-d6) δ = 7.85-7.71 (m, 1H), 7.37-7.28 (m, 2H), 7.14-7.11 (dd, J = 9.2Hz, 4.4Hz, 1H), 4.15 (s ,2H),3.42-3.22(m,2H),2.82-2.67(m,2H),2.57(s,3H),1.69-1.57(m,2H),1.48-1.43(m,1H),1.30(s,6H).
[0501] Comparative Example 1:
[0502] Reference compound 1 was synthesized by referring to the synthesis method of Example 47 of patent CN201480040447.
[0503] 1 H NMR (400MHz, DMSO-d6) δ = 8.33 (s, 1H), 8.15 (s, 1H), 7.93-7.92 (m, 1H), 7.52-7.50 (m, 1H), 6.87-6.84 (m ,1H), 4.32(s,2H), 3.13-3.06(m,4H), 2.15(s,3H), 1.86-1.84(m,2H), 1.69-1.65(m,1H), 1.33(s,6H). MS(ESI,m / z)290.2[M+H] + .
[0504] Biological test evaluation
[0505] The present invention is further described below in conjunction with test examples.
[0506] Test Example 1 Determination of the agonist activity of the compounds of the present invention on human somatostatin type IV receptor SSTR4
[0507] 1. Purpose of the experiment
[0508] Cell-based human SSTR4 cAMP assay was used to determine the agonist effect of the test compounds on the SSTR4 receptor.
[0509] 2. Experimental materials and equipment
[0510] 2.1 Experimental Reagents and Consumables
[0511] 2.2 Experimental instruments and equipment
[0512] 3. Experimental Methods
[0513] 3.1 Cell culture and reagent preparation
[0514] 1) Cell line: Flp-In-CHO-SSTR4 stable pool (provided by Pharmaron Pharmaceuticals, Inc., constructed using the Invitrogen Flp-In system)
[0515] 2) Complete medium: Complete medium: Ham's F-12K + 10% fetal bovine serum + 1x penicillin-streptomycin (PS) + 600 μg / mL hygromycin B
[0516] 3) Cell seeding medium: Ham's F-12K + 10% FBS
[0517] 4) Experimental buffer: 1X HBSS + 20mM HEPES + 0.1% BSA + 500μM IBMX
[0518] 3.2 Preparation of working solution of test compound
[0519] The test compound was dissolved in DMSO to prepare a 10 mM stock solution and diluted to a maximum starting concentration of 1000 nM during the experiment.
[0520] 3.3 EC of test compound 50 Determination of value
[0521] 1) Flp-In-CHO-SSTR4 cells were cultured in complete medium at 37°C, 5% CO2 until they reached 70% to 90% confluency.
[0522] 2) After TrypLE digestion, the cells were resuspended in inoculation medium and seeded into a 384-well cell culture plate (PE culture 384 plate) at a density of 7,000 cells per well. The cells were cultured at 37° C. in 5% CO 2 overnight.
[0523] 3) Prepare the positive control compound and the test compound working solution (8X).
[0524] 4) Remove the cell culture plate and centrifuge at 200g for 5 seconds at room temperature to remove the culture medium. Then quickly add 15 μL of assay buffer to each well and centrifuge at 200g for 5 seconds at room temperature to mix evenly.
[0525] 5) Add 2.5 μL of the 8X compound working solution diluted in step 3 to the corresponding test wells, centrifuge at 200g for 5 seconds at room temperature, and incubate at 37°C for 10 minutes.
[0526] 6) Prepare 4 μM Forskolin working solution (8X).
[0527] 7) Remove the cell plate and equilibrate to room temperature. Then add 2.5 μL of the 8X Forskolin working solution prepared in step 6 to the corresponding test wells. Incubate at 200g for 5 seconds at room temperature and incubate at 37°C for 30 minutes.
[0528] 8) Freeze-thaw Eu-cAMP tracer and Uliaght-anti cAMP, dilute Eu-cAMP tracer 50 times and Uliaght-anti cAMP 150 times with detection buffer.
[0529] 9) Add 10 μL of Eu-cAMP tracer to all experimental wells and add 10 μL of Uliaght-anti cAMP to the remaining experimental wells.
[0530] 10) The reaction plate was centrifuged at 200 g for 30 seconds at room temperature, allowed to stand at 25°C for 1 hour, and data were collected using Envision.
[0531] 3.4 Data Analysis
[0532] Calculate compound EC using GraphPad nonlinear fitting formula 50 .
[0533] Z' factor = 1-3 × (standard deviation Max + standard deviation Min) / (average Max - average Min)
[0534] Coefficient of variation Max = (standard deviation Max / average Max) × 100%
[0535] Coefficient of variation Min = (standard deviation Min / average value Min) × 100%
[0536] S / B=Singal / Background signal value / background value
[0537] Negative control (Min): experimental buffer
[0538] Positive control (Max): 1,000nM of Somatostatin 14
[0539] Calculate compound EC using GraphPad nonlinear fitting formula 50 :
[0540] Y=Bottom+(Top-Bottom) / (1+10^((LogEC 50 -X)×HillSlope))
[0541] X: log value of compound concentration; Y: Activation%.
[0542] 4. Experimental Results
[0543] It can be seen from the data in the above table that the compounds of the present invention have excellent in vitro activity and can produce significant agonist activity on human somatostatin type IV receptor.
[0544] Test Example 2 Pharmacokinetic Determination in SD Rats
[0545] 1. Purpose of the study
[0546] SD rats were used as test animals to study the pharmacokinetic behavior of the following compound examples in rat plasma after oral administration at a dose of 10 mg / kg.
[0547] 2. Test methods
[0548] 2.1. Investigational Drugs
[0549] The examples and reference compounds of the present invention were prepared in-house.
[0550] 2.2. Experimental animals
[0551] Male SPF SD rats, weighing (200 ± 20) g, were purchased from Sibeifu (Beijing) Biotechnology Co., Ltd., with animal production license number SCXK (Beijing) 2019-0010.
[0552] 2.3. Preparation of experimental drugs
[0553] Drug preparation: The drug concentration was prepared to 1 mg / mL in a Tween 80 + 0.5% MC (v / v 1:99) solution.
[0554] 2.4. Administration:
[0555] Male SPF SD rats were fed adaptively for 3-4 days and then given the drug by gavage at a dose of 10 mg / kg in a volume of 10 mL / kg.
[0556] 2.5. Sample collection
[0557] Before administration (0h) and after administration, blood was collected from rats at 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, and 24h. Blood was collected by fundus puncture, and the blood volume was about 0.5mL. The blood was placed in a labeled EDTA-K2 anticoagulant tube. Immediately after blood collection, the tube was gently and completely inverted 3 times to mix with the anticoagulant, and immediately centrifuged at 4500rpm in an ice water bath at 4°C for 10min. After the centrifugation operation, the plasma was promptly divided into EP tubes with corresponding labels and stored in a -80°C refrigerator.
[0558] 2.6. Sample testing
[0559] This experiment used a simple validated LC-MS / MS method to determine the concentrations of Example X and Example Y in plasma after administration.
[0560] 2.6.1. Sample Processing: Place 20 μL of blank plasma in a 96-deep-well plate pre-added with 20 μL of internal standard working solution. Add 400 μL of precipitant methanol, vortex for 10 min, and centrifuge at 4000 rpm for 15 min. Place 200 μL of the supernatant in another 96-deep-well plate pre-added with 200 μL of ultrapure water. Vortex for 5 min, centrifuge at 4000 rpm for 3 min, and perform LC-MS / MS analysis with an injection volume of 5 μL.
[0561] 2.6.2. Liquid chromatography-mass spectrometry analysis:
[0562] 1) Liquid phase conditions
[0563] Chromatographic column: CAPCELL PAK C18 5.0μm, 2.0×50mm; No.: 217
[0564] Pressure: 10Mpa
[0565] Pre-column: Pheromone guard column
[0566] Column temperature: 40°C
[0567] Injection volume: 1 μL
[0568] Injector temperature: 4°C
[0569] Run time: 4.0 minutes
[0570] Flow rate: 0.6 mL / min
[0571] Column pressure: 10Mpa
[0572] Needle washing solution: 50% acetonitrile in water
[0573] Needle wash mode: Before and after aspiration
[0574] Mobile phase A: 0.1% formic acid in 5 mM ammonium acetate in water
[0575] Mobile phase B: 0.1% formic acid, 5 mM ammonium acetate, 90% acetonitrile in water
[0576] Elution program and mobile phase distribution ratio: Gradient elution is shown in Table 1 below.
[0577] Table 1
[0578] 2) Mass spectrometry conditions:
[0579] Ion detection method: Multiple reaction ion monitoring (MRM)
[0580] Ionic polarity: positive ion
[0581] Ionization method: pneumatically assisted electrospray ionization (ESI)
[0582] CAD: 8
[0583] CUR: 40psi
[0584] GS1: 50psi
[0585] GS2: 50psi
[0586] TEM: 600°C
[0587] IS: 4500v
[0588] 3. Test results and analysis
[0589] The main pharmacokinetic parameters were calculated using WinNonlin 7.0. The results of the rat pharmacokinetic experiment are shown in Table 2 below.
[0590] Table 2 Results of rat pharmacokinetic test
[0591] 4. Experimental Conclusion
[0592] From the results of the rat pharmacokinetic test in the table, it can be seen that the compounds of the present invention showed good oral absorption characteristics, the exposure amount AUC and the maximum blood concentration C max All of them performed well and were better than Comparative Example 1.
[0593] Test Example 3: Drug Efficacy Test in Rat CFA Model
[0594] Objective: To evaluate the efficacy of the examples in the CFA model of Sprague-Dawley (SD) rats using the mechanical allodynia test.
[0595] Methods: Male Sprague-Dawley rats aged 7 to 8 weeks were selected and 50 μl of CFA stock solution was injected into the center of the plantar surface of the left hind paw of the rats. 24 hours after modeling, animals with a paw withdrawal threshold of less than 5g were screened based on the basal value of mechanical pain perception. The rats were divided into groups, with 8 animals in each group. The paw withdrawal threshold of the animals was tested using fibers 2 hours, 4 hours, and 6 hours after a single oral administration of the example molecule.
[0596] The results are shown in FIG1 , which show that Examples 4, 5, 9, and 23 can inhibit mechanical allodynia induced by the CFA model in rats after oral administration at 30 mg / kg, and the analgesic effect is significantly better than that of the reference compound (Comparative Example 1).
[0597] Test Example 4: Determination of drug efficacy for sciatica pain in rats
[0598] Objective: To evaluate the efficacy of the examples in the CCI model of sciatica pain in Sprague-Dawley (SD) rats using a mechanical allodynia test.
[0599] Methods: Male Sprague-Dawley rats aged 7-8 weeks were selected and underwent CCI surgery on Day 1. The rats were acclimated on Days 11-13, and baseline mechanical pain perception (PWT) testing was performed on Day 14. The rats were divided into groups based on baseline, with 8 animals per group. Paw withdrawal thresholds were measured using fibers 2, 4, and 6 hours after a single oral administration of the example molecules.
[0600] The results are shown in FIG2 , which indicate that Example 5 can inhibit mechanical allodynia induced by the CCI model in rats after oral administration.
Claims
1. A compound as shown in formula I or a pharmaceutically acceptable salt thereof, in, R 1 H or C 1-6 alkyl; R 2 H or C 1-6 alkyl; R 3 and R 4 Independently H, C 1-6 Alkyl or C 3-6 Cycloalkyl; Or, R 3 , R 4 Together with the carbon atom it is attached to, it forms C 3-6 Cycloalkyl; L is a bond, -CH 2 -、-CH 2 -CH 2 -or-CH 2 -O-; X 1 CR X1 or N; X 2 CR X2 or N; X 3 CR X3 or N; X 4 CR X4 or N; R X1 , R X2 , R X3 , R X4 and R 5 are independently H, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkynyl, 1, 2 or 3 R a Substituted C 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)-C 1-4 Alkyl or "a 4-membered heterocycloalkyl group having one heteroatom selected from N, O and S"; R X1 , R X2 , R X3 , R X4 and R 5 At least one of them is C 2-6 Alkynyl, 1, 2 or 3 R a Substituted C 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)-C 1-4 Alkyl or "a 4-membered heterocycloalkyl group having one heteroatom selected from the group consisting of N, O and S"; R a are independently hydroxy, halogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, "a 3- to 6-membered heterocycloalkyl group having 1, 2 or 3 heteroatoms selected from N, O and S and having 1 or 2 heteroatoms".
2. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1, It is characterized in that The compound as shown in formula I satisfies one or more of the following conditions: (1)R 1 , R 2 , R X1 , R X2 , R X3 , R X4 and R 5 In the C 1-6 Alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl; (2)R 3 , R 4 , and R a In the C 1-6 Alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example, methyl; (3)R 1 , R 2 , R 3 , R 4 , R X1 , R X2 , R X3 , R X4 , R 5 and R a In the C 3-6 Cycloalkyl is independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; (4)R 3 , R 4 Together with the carbon atom it is attached to, it forms C 3-6 In the cycloalkyl group, the C 3-6 Cycloalkyl is independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; (5)R a In the C 3-6 Cycloalkyl is independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; for example, cyclopropyl; (6)R X1 , R X2 , R X3 , R X4 and R 5 In the C 1-6 The haloalkyl is independently C 1-4 Haloalkyl; (7)R X1 , R X2 , R X3 , R X4 and R 5 In the C 1-6 Alkoxy is independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy; (8)R X1 , R X2 , R X3 , R X4 and R 5 In the C 1-6 The haloalkoxy groups are independently C 1-4 Haloalkoxy; (9)R 5 In the C 2-6 Alkynyl and the substituted C 2-6 C in the alkynyl group 2-6 The alkynyl groups are independently (10)R X1 , R X2 , R X3 and R X4 In, the -OC 3-6 Cycloalkyl is (11)R 5 In, the -OC 3-6 Cycloalkyl is For example (12)R X1 , R X2 , R X3 , and R X4 In the above, the "4-membered heterocycloalkyl group having one heteroatom selected from N, O and S" is oxetane; (13)R 5 In the above, the "4-membered heterocycloalkyl group having one heteroatom selected from N, O and S" is an oxetane group, for example (14)R a In the above, the "heteroatom" is selected from 1, 2 or 3 of N, O and S, and the number of heteroatoms is 1 "3-6 membered heterocycloalkyl having one, two or three members" means "3-6 membered heterocycloalkyl having one heteroatom selected from O"; for example, oxetanyl; (15)R X1 , R X2 , R X3 , and R X4 In the above-mentioned -C(=O)-C 1-4 The alkyl groups are independently (16)R 5 In the above-mentioned -C(=O)-C 1-4 The alkyl groups are independently For example (17)R X1 , R X2 , R X4 and R 5 wherein the halogen is F, Cl, Br or I; (18)R X3 wherein the halogen is F, Cl, Br or I; for example, F or Cl; (19)R a wherein the halogen is F, Cl, Br or I; for example, F.
3. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1, It is characterized in that The compound as shown in formula I satisfies one or more of the following conditions: (1)R 1 is H; (2)R 2 is H; (3)R 3 and R 4 Independently for C 1-6 alkyl; (4) L is -CH 2 -O-; (5)X 1 CR X1 or N;X 2 CR X2 ;X 3 CR X3 ;X 4 CR X4 ; (6)R X1 , R X2 , R X3 and R X4 are independently H, halogen or -CN; Preferably, R X1 , R X2 and R X4 independently H; R X3 is H, halogen or -CN; More preferably, R X1 , R X2 and R X4 independently H; R X3 is halogen or -CN; (7)R 5 C 2-6 Alkynyl, 1, 2 or 3 R a Substituted C 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)-C 1-4 Alkyl or "a 4-membered heterocycloalkyl group having one heteroatom selected from N, O and S"; Preferably C 2-6 Alkynyl, -C(=O)-C 1-4 Alkyl, 1, 2 or 3 R a Substituted C 2-6 Alkynyl; (8)R a are independently hydroxy, halogen, C 1-6 Alkyl, C 3-6 The cycloalkyl group or heteroatom is selected from N, O and S 1, 2 or 3 kinds of 3-6 membered heterocycloalkyl radicals, with 1 or 2 heteroatoms.
4. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1, It is characterized in that The compound as shown in formula I satisfies one or more of the following conditions: (1)R 3 and R 4 independently -CH 3 ; (2)R 5 for (3) for For example 5. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1, It is characterized in that The compound as shown in formula I is selected from the following schemes: Option 1: R 1 is H; R 2 is H; R 3 and R 4 Independently for C 1-6 alkyl; L is -CH 2 -O-; X 1 CR X1 or N;X 2 CR X2 ;X 3 CR X3 ;X 4 CR X4 ; R X1 , R X2 , R X3 and R X4 are independently H, halogen or -CN; R 5 C 2-6 Alkynyl, 1, 2 or 3 R a Substituted C 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)-C 1-4 Alkyl or "a 4-membered heterocycloalkyl group having one heteroatom selected from N, O and S"; R a are independently hydroxy, halogen, C 1-6 Alkyl, C 3-6 Cycloalkyl or "a 3- to 6-membered heterocycloalkyl group having 1, 2 or 3 heteroatoms selected from N, O and S and 1 or 2 heteroatoms"; Scheme 2: The compound represented by formula I is a compound represented by formula IA: Among them, X 1 , R X3 and R 5 The definition as in any one of claims 1 to 4; Preferably, in Formula IA, R 5 C 2-6 Alkynyl or -C(=O)-C 1-4 Alkyl; R X3 is halogen or -CN.
6. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1, It is characterized in that R X1 , R X2 , R X3 , and R X4 are independently H, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkynyl, 1, 2 or 3 R a Substituted C 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)-C 1-4 Alkyl or "a 4-membered heterocycloalkyl group having one heteroatom selected from N, O and S"; R 5 C 2-6 Alkynyl or 1, 2 or 3 R a Substituted C 2-6 Alkynyl; R 5 Preferably C 2-6 Alkynyl.
7. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 6, It is characterized in that R X1 , R X2 , R X3 , and R X4 are independently H, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkynyl, 1, 2 or 3 R a Substituted C 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)-C 1-4 Alkyl or "a 4-membered heterocycloalkyl group having one heteroatom selected from N, O and S"; and R X1 , R X2 , R X3 , and R X4 At least one is not H; preferably R X3 Not for H.
8. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1, It is characterized in that The compound as shown in formula I is selected from any of the following compounds:
9. A method for preparing a compound as shown in formula I, It is characterized in that The method comprises the following steps: mixing a compound represented by formula II with an acid in a solvent to obtain a compound represented by formula I; R 1 is H; PG is an amino protecting group (such as a Boc group); R 2 ,R 3 ,R 4 ,R 5 ,X 1 ,X 2 ,X 3 ,X 4 and L are as defined in any one of claims 1-6.
10. A compound as shown in formula II or a pharmaceutically acceptable salt thereof, R 2 ,R 3 ,R 4 ,R 5 ,X 1 ,X 2 ,X 3 ,X 4 and L is as defined in any one of claims 1 to 7; PG is an amino protecting group (eg, a Boc group).
11. The compound of formula II or a pharmaceutically acceptable salt thereof according to claim 10, It is characterized in that The compound shown in formula II is selected from any one of the following compounds:
12. A pharmaceutical composition, It is characterized in that The pharmaceutical composition comprises (a therapeutically effective amount of) a compound as shown in formula I according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical excipient.
13. Use of the compound of formula I according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 12 in the preparation of an SSTR4 receptor agonist.
14. Use of a compound of formula I as described in any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described in claim 12 for preparing a medicament for treating and / or preventing a disease related to the central nervous system.
Citation Information
Patent Citations
Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
CN101838271A
New somatostatin receptor subtype 4 (SSTR4) agonists
CN105473574A
Nitrogen-containing saturated heterocyclic compound and preparation method, pharmaceutical composition and application thereof
CN113717161A
Fused ring compound and preparation method, pharmaceutical composition and application thereof
CN113717167A
Nitrogen-containing heterocyclic compound, pharmaceutical composition and application
CN113929693A
